image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
89b7ebafcef7fc23f1f5cc77421983398ab71210b224518d4df3232da5a25e53.png | simple | <table><tr><td>mRNA</td><td>Primer</td></tr><tr><td>Mouse B2m</td><td>Fwd 5′-ACCGTCTACTGGGATCGAGA-3′</td></tr><tr><td></td><td>Rev 5′-TGCTATTTCTTTCTGCGTGCAT-3′</td></tr><tr><td>Mouse Rpl13a</td><td>Fwd 5′-AGAAGCAGATCTTGAGGTTACGG-3′</td></tr><tr><td></td><td>Rev 5′-GTTCACACCAGGAGTCCGTT-3′</td></tr><tr><td>Mouse Aqp5</td><td>Fwd 5′-CTTGTGGGGATCTACTTCACCG-3′</td></tr><tr><td></td><td>Rev 5′-AAGTAGAGGATTGCAGCCAGG-3′</td></tr><tr><td>Mouse T1α</td><td>Fwd 5′-TCACCCCAATAGAGATGGCTTG-3′</td></tr><tr><td></td><td>Rev 5′-GGGCAAGTTGGAAGCTCTCTT-3′</td></tr><tr><td>Mouse Rage</td><td>Fwd 5′-CACAGGCTCTGTGGGTGAG-3′</td></tr><tr><td></td><td>Rev 5′-TTCAGCTCTGCACGTTCCTC-3′</td></tr><tr><td>Mouse Con43</td><td>Fwd 5′-TCCTTTTCCTTTGACTTCAGCCTC-3′</td></tr><tr><td></td><td>Rev 5′-TCTGAAAATGAAGAGCACCGACA-3′</td></tr><tr><td>Mouse Sftpc</td><td>Fwd 5′-GGAGCACCGGAAACTCAGAA-3′</td></tr><tr><td></td><td>Rev 5′-GGAGCCGCTGGTAGTCATAC-3′</td></tr></table> |
d25ab6b2494f868ba741ae8b4a7fa42019d4b5e4aa52428342c773e1a4f4b1ab.png | complex | <table><tr><td colspan="6">Base case ICER calculations</td><td colspan="4">Threshold analysis*: probability of cost-effective at alternative values of willingness to pay for a QALY(%)</td></tr><tr><td></td><td>Mean total cost (£)</td><td>Incremental cost (£)</td><td>Mean QALY</td><td>Incremental QALY</td><td>ICER (£/QALY)</td><td>£10,000</td><td>£20,000</td><td>£30,000</td><td>£50,000</td></tr><tr><td>Fluid loading</td><td>10,373</td><td></td><td>0.3527</td><td></td><td></td><td>84.4</td><td>86.5</td><td>89.4</td><td>92.0</td></tr><tr><td>Fluid control</td><td>11,739</td><td>-1,366</td><td>0.3175</td><td>0.0352</td><td>Dominated</td><td>15.6</td><td>13.5</td><td>10.6</td><td>8.0</td></tr><tr><td>Adjusted differences(95% CI; <i>P-</i>value)*</td><td></td><td>-2,047(-6,947 to 2,854; <i>P </i>= 0.413)</td><td></td><td>0.0431(-0.0171 to 0.1033; <i>P </i>= 0.161)</td><td></td><td></td><td></td><td></td><td></td></tr></table> |
46f82fc633f868703cb278df6103373cddce453cc70f48322af7aac7efc4d265.png | complex | <table><tr><td>Name</td><td>Sequence</td><td>Genome Position*</td><td>Expected Size (bp)</td><td>Reference</td></tr><tr><td>p20F</td><td>5' ACAATATGCGAGCTTACTTTA 3' </td><td>17691–17710</td><td rowspan="2">555</td><td rowspan="2">[18]</td></tr><tr><td>p20R</td><td>5' AACCTACACGCAAGATGGA 3' </td><td>18229–18246</td></tr><tr><td>p23F</td><td>5' GTCTCTCCATCTTGCGGTGTAG 3'</td><td>18224–18244</td><td rowspan="2">733</td><td rowspan="4">[30]</td></tr><tr><td>p23R</td><td>5' CAATCAGATGAAGTGGTG3' </td><td>18941–18957</td></tr><tr><td>p25F</td><td>5' TGAATTATGGACGACGAAAC 3'</td><td>16079–16097</td><td rowspan="2">676</td></tr><tr><td>p25R</td><td>5' TCAACGTGTGTTGAATTTCCC 3'</td><td>16736–16755 </td></tr></table> |
27b434f754ca7c8c8e229585a2f7665f51428473c8fd8a23b41926739772263b.png | simple | <table><tr><td>Plant material</td><td>Deposit number</td><td>Deposit location</td><td>Name of herbarium</td></tr><tr><td><i>Piper aduncum</i></td><td>10,480</td><td>INPA<sup>1</sup></td><td>INPA herbarium</td></tr><tr><td><i>Piper tuberculatum</i></td><td>6,797</td><td>IFAM<sup>2</sup></td><td>EAFM herbarium</td></tr><tr><td><i>Piper hispidum</i></td><td>6,796</td><td>IFAM</td><td>EAFM herbarium</td></tr><tr><td><i>Piper marginatum</i></td><td>6,798</td><td>IFAM</td><td>EAFM herbarium</td></tr><tr><td><i>Piper callosum</i></td><td>6,794</td><td>IFAM</td><td>EAFM herbarium</td></tr><tr><td><i>Piper hispidinervum</i></td><td> </td><td>IFAM</td><td>EAFM herbarium</td></tr><tr><td><i>Piper</i> sp.</td><td> </td><td>IFAM</td><td>EAFM herbarium</td></tr></table> |
fa15271ec8771b01baa4864046acbc36f6388a434f83e40a09f2134102f2daa1.png | complex | <table><tr><td>Source</td><td><i>P</i></td><td></td><td rowspan="2">95% CI</td></tr><tr><td>Model</td><td>0.005</td><td>Odds Ratio</td></tr><tr><td>Diabetes Mellitus</td><td>0.017</td><td>1.823</td><td>1.111–2.99</td></tr><tr><td>Male Gender</td><td>0.048</td><td>0.616</td><td>0.381–0.998</td></tr><tr><td>Chronic Heart Failure</td><td>0.058</td><td>1.974</td><td>0.972–4.009</td></tr><tr><td>Chronic Renal Failure</td><td>0.083</td><td>1.727</td><td>0.928–3.215</td></tr><tr><td>MDH/Community</td><td>0.125</td><td>1.561</td><td>0.879–2.774</td></tr><tr><td>Alcohol abuse</td><td>0.217</td><td>0.288</td><td>0.032–2.62</td></tr><tr><td>Age ≥ 65</td><td>0.26</td><td>1.01</td><td>0.993–1.027</td></tr><tr><td>Liver disease</td><td>0.413</td><td>0.491</td><td>0.085–2.846</td></tr><tr><td>Lung disease</td><td>0.75</td><td>1.106</td><td>0.595–2.056</td></tr><tr><td>Ischaemic Heart Disease</td><td>0.944</td><td>1.022</td><td>0.559–1.869</td></tr></table> |
10862323c869c1eb1281ef215106b52eeeb6646a123076654dd5154c22468b2e.png | complex | <table><tr><td colspan="2">Annual drug expenses (USD) (n = 116), mean ± SD</td><td>T</td><td><i>p</i> value</td></tr><tr><td>Preoperative</td><td>660.08 ± 426.05</td><td rowspan="3">14.877</td><td rowspan="3"><0.001</td></tr><tr><td>Postoperative 1 year</td><td>65.12 ± 138.23</td></tr><tr><td>Difference in expenses</td><td>594.96 ± 430.74</td></tr></table> |
eaa5dd3fe3539338e7d23a7e535b2d51c6859ed46f2384ebe2361b4e73df1694.png | simple | <table><tr><td>ICD-10 code</td><td>Criteria for Appropriate Antibiotic Prescription</td></tr><tr><td>H65 Nonsuppurative otitis mediaH66 Suppurative and nonspecified otitis media</td><td>H65 must meet both conditions: presence of Acute Bilateral Otitis media AND age < 2H65 or H66 with presence of otorrhea</td></tr><tr><td>J01 Acute sinusitis</td><td>Must meet all conditions: Fever of >38C°, purulent discharge and facial pain</td></tr><tr><td>JO2 Acute pharyngitisJO3 Acute tonsillitis</td><td>Must meet 3 of the following CENTOR criteria:­ Presence of tonsilar exudate­ Presence of painful anterior cervical lymphadenopathy or lymphadenitis­ Fever (> 38°)­ Absence of cough</td></tr><tr><td>JOO Acute nasopharyngitis [common cold]JO1 Acute sinusitisJO2 Acute pharyngitisJO3 Acute tonsillitisJO4 Acute laryngitis and tracheitisJO5 Acute obstructive laryngitis [croup] and epiglotitisJO6 Acute upper respiratory infections of multiple and unspecified sitesJ10 Influenza due to other identified influenza virusJ11 Influenza due to unidentified influenza virus</td><td>Must meet any of the following criteria:­ Presence of one or more of the following comorbidities: Cardiac, Pulmonary, Renal, Hepatic, Neuromuscular, Immunosuppression, Cystic Fibrosis, Diabetes Mellitus.- OR­ Age < 2 years old AND history of prematurityOR­ Age > 65 years old AND presence of cough AND two or more of the following:▪ Hospitalized in 2014▪ Diabetes mellitus▪ History of cardiac arrest▪ Current use of corticosteroidsOR­ Age > 80 years old AND presence of cough AND one or more of the following:▪ Hospitalized in 2014▪ Diabetes mellitus▪ History of cardiac arrest▪ Current use of corticosteroids</td></tr></table> |
8af24a21aeab8d3871795eb6cc31f1304ecf77318fd494ea169de01ffca32599.png | complex | <table><tr><td rowspan="2"> </td><td>Control</td><td colspan="3">JOAG</td><td colspan="3">AOAG</td></tr><tr><td>N (%)</td><td>N (%)</td><td>OR (95%CI)</td><td><i>P</i>*</td><td>N (%)</td><td>OR (95%CI)</td><td><i>P</i>*</td></tr><tr><td>Non-smoker</td><td>55 (43.7)</td><td>14 (41.2)</td><td>4.33 (0.12-5.84 × 10<sup>5</sup>)</td><td>0.692</td><td>31 (33.7)</td><td>1.03 (0.52-2.08)</td><td>0.925</td></tr><tr><td>Smoker</td><td>71 (56.3)</td><td>16 (58.8)</td><td colspan="2"> </td><td>61 (66.3)</td><td colspan="2"> </td></tr></table> |
4dcaea5ebb1eedc893e2c63b42d5e93d6d2318ea0248ddfab0261a47b49c28d2.png | simple | <table><tr><td>Preparedness</td><td>Female</td><td>Male</td></tr><tr><td>Personal:</td><td></td><td></td></tr><tr><td>Yes</td><td>8</td><td>19</td></tr><tr><td>No</td><td>11</td><td>7</td></tr><tr><td>Uncertain</td><td>3</td><td>4</td></tr><tr><td>Community: </td><td></td><td></td></tr><tr><td>Yes</td><td>5</td><td>5</td></tr><tr><td>No</td><td>11</td><td>15</td></tr><tr><td>Uncertain / Improving</td><td>0</td><td>6</td></tr></table> |
e7018bb54696e2f3b56dc9b6fc6ee896255d97c61332dbf8872c8b7422a59ac4.png | complex | <table><tr><td rowspan="2">Filtered times</td><td colspan="3">Repeat</td><td colspan="2">Contigs (kb)</td><td colspan="3">Accuracy (%)</td><td rowspan="2">Genome coverage (%)</td></tr><tr><td>TRC</td><td>CNRC</td><td>NNC</td><td>N50</td><td>Max </td><td>CN-accuracy</td><td>Rep-accuracy</td><td>C-accuracy</td></tr><tr><td>1</td><td>11</td><td>Appendix</td><td>801</td><td>0.3</td><td>2.3</td><td>100</td><td>66.8</td><td>100</td><td>53.4</td></tr><tr><td>2</td><td>12</td><td>Appendix</td><td>418</td><td>1.8</td><td>7.6</td><td>100</td><td>82.1</td><td>100</td><td>101.9</td></tr><tr><td>3</td><td>13</td><td>Appendix</td><td>1025</td><td>0.3</td><td>2.3</td><td>100</td><td>68</td><td>100</td><td>77.4</td></tr></table> |
efb5e27aa44941aa87c0533fd9d52e4510583be182f892c43aa4e2e19a9f9ad6.png | simple | <table><tr><td></td><td>Synchronous combined surgery (<i>n</i> = 25) (35.7%)</td><td>Synchronous “bowel first” (<i>n</i> = 14) (20%)</td><td>Metachronous (<i>n</i> = 31) (44.3%)</td><td>Total (<i>n</i> = 70)</td><td><i>p</i> value</td></tr><tr><td>Age (years, range)</td><td>68 (34–85)</td><td>75 (46–82)</td><td>70 (52–85)</td><td>69.5 (34–85)</td><td>0.730</td></tr><tr><td>Sex (<i>n</i>, %)</td><td></td><td></td><td></td><td></td><td>0.683</td></tr><tr><td> Male</td><td>15 (60%)</td><td>9 (64.3%)</td><td>16 (51.6%)</td><td>40 (57.1%)</td><td></td></tr><tr><td> Female</td><td>10 (40%)</td><td>5 (35.7%)</td><td>15 (48.4%)</td><td>30 (42.9%)</td><td></td></tr><tr><td>Bowel obstruction (<i>n</i>, %)</td><td>5 (20%)</td><td>7 (50%)</td><td>7 (22.6%)</td><td>19 (27.1%)</td><td>0.097</td></tr><tr><td>Site of primary tumor (<i>n</i>, %)</td><td></td><td></td><td></td><td></td><td>0.343</td></tr><tr><td> Right colon</td><td>8 (32%)</td><td>2 (14.3%)</td><td>11 (35.5%)</td><td>21 (30%)</td><td></td></tr><tr><td> Left colon</td><td>17 (68%)</td><td>12 (85.7%)</td><td>20 (64.5%)</td><td>49 (70%)</td><td></td></tr><tr><td>CHT before liver surgery</td><td>2 (8%)</td><td>11 (78.6%)</td><td>20 (64.5%)</td><td>33 (47%)</td><td><0.0001</td></tr></table> |
de317b6c8154376879e124fa267718fc4f27fd6b1587e1414ef3f466007d62a3.png | complex | <table><tr><td>Characteristics</td><td></td><td>Range</td></tr><tr><td>No. of patients</td><td>1085</td><td></td></tr><tr><td>Age, mean (SD)</td><td>44.72(12.12)</td><td>13-82</td></tr><tr><td>No. of women (%)</td><td colspan="2">846(77.97%)</td></tr><tr><td>Educational degree</td><td>Primary school</td><td>85</td></tr><tr><td></td><td>Junior high</td><td>60</td></tr><tr><td></td><td>Senior high</td><td>211</td></tr><tr><td></td><td>College</td><td>576</td></tr><tr><td></td><td>Post-graduate</td><td>153</td></tr></table> |
b012a742dd55296969a39542d0a03fd417a34d2799853a2c14ff39d044e65465.png | simple | <table><tr><td>Variable</td><td>HIV-negative</td><td>HIV-infected,</td><td>HIV-infected,</td></tr><tr><td>Proportion (%)</td><td>control</td><td>ART-naive</td><td>on ART</td></tr><tr><td>Median [IQR]</td><td>(number = 153)</td><td>(number = 151)</td><td>(number = 150)</td></tr><tr><td>Female</td><td>94 (61.4%)</td><td>89 (58.9%)</td><td>115 (76.7%)</td></tr><tr><td>Age (in years)</td><td>38 [32 to 46]</td><td>37 [32 to 44]</td><td>40 [38 to 47]</td></tr><tr><td>Education level</td><td></td><td></td><td></td></tr><tr><td>Incomplete primary</td><td>27 (17.7%)</td><td>25 (16.6%)</td><td>30 (20.0%)</td></tr><tr><td>Complete primary</td><td>82 (53.6%)</td><td>98 (64.9%)</td><td>94 (62.7%)</td></tr><tr><td>Secondary and above</td><td>44 (28.8%)</td><td>28 (18.5%)</td><td>26 (17.3%)</td></tr><tr><td>Work type</td><td></td><td></td><td></td></tr><tr><td>Manual</td><td>109 (71.2%)</td><td>114 (75.5%)</td><td>105 (70.0%)</td></tr><tr><td>Office</td><td>44 (28.8%)</td><td>37 (24.5%)</td><td>45 (30.0%)</td></tr><tr><td>Vigorous work</td><td>15 (9.8%)</td><td>21 (13.9%)</td><td>33 (22.0%)</td></tr><tr><td>Mode of transportation</td><td></td><td></td><td></td></tr><tr><td>Walking or bicycle</td><td>130 (85.0%)</td><td>110 (72.9%)</td><td>117 (78.0%)</td></tr><tr><td>Motorized vehicle</td><td>23 (15.0%)</td><td>41 (27.1%)</td><td>33 (22.0%)</td></tr><tr><td>Ease of Living Index<sup>a</sup></td><td></td><td></td><td></td></tr><tr><td>Low</td><td>86 (56.2%)</td><td>94 (62.3%)</td><td>81 (54.0%)</td></tr><tr><td>Middle</td><td>20 (13.1%)</td><td>24 (15.9%)</td><td>26 (17.3%)</td></tr><tr><td>Higher</td><td>47 (30.7%)</td><td>33 (21.9%)</td><td>43 (28.7%)</td></tr><tr><td>Ever smoking</td><td>6 (3.9%)</td><td>16 (10.6%)</td><td>10 (6.7%)</td></tr><tr><td>Current smoker</td><td>5 (3.3%)</td><td>4 (2.7%)</td><td>0</td></tr><tr><td>Fruit and vegetables servings/week</td><td>6 [4-12]</td><td>8 [5-12]</td><td>9 [6 to 13]</td></tr><tr><td>Sugary drinks/day</td><td>1 [0.5 to 2]</td><td>1 [0.5 to 2]</td><td>1 [1 to 2]</td></tr><tr><td>Current alcohol use</td><td></td><td></td><td></td></tr><tr><td>None</td><td>119 (77.8%)</td><td>120 (79.5%)</td><td>136 (90.7%)</td></tr><tr><td>< once/week</td><td>19 (12.4%)</td><td>16 (10.6%)</td><td>8 (5.3%)</td></tr><tr><td>≥ once/week</td><td>15 (9.8%)</td><td>15 (9.9%)</td><td>6 (4.0%)</td></tr><tr><td>Body Mass Index (BMI) in kg/m<sup>2</sup></td><td>23.8 [22.3 to 25.8]</td><td>22 [20.2 to 24.3]</td><td>23.7 [21.5 to 27.9]</td></tr><tr><td>BMI <18.5</td><td>5 (3.3%)</td><td>18 (11.9%)</td><td>4 (2.7%)</td></tr><tr><td>BMI 18.5 to 25</td><td>104 (68.0%)</td><td>113 (74.8%)</td><td>80 (53.3%)</td></tr><tr><td>BMI 25 to 30</td><td>33 (21.6%)</td><td>9 (6.0%)</td><td>45 (30.0%)</td></tr><tr><td>BMI >30</td><td>11 (7.2%)</td><td>11 (7.3%)</td><td>21 (14.0%)</td></tr><tr><td>Waist-hip ratio</td><td>0.84 [0.82 to 0.87]</td><td>0.84 [0.80 to 0.89]</td><td>0.87 [0.82 to 0.91]</td></tr><tr><td>Central obesity<sup>b</sup></td><td>44 (29.1%)</td><td>56 (37.1%)</td><td>78 (52.0%)</td></tr><tr><td>Diabetes mellitus</td><td>0</td><td>1 (0.7%)</td><td>1 (0.7%)</td></tr><tr><td>Current CD4 T-cell count in cells/μL</td><td>NA</td><td>215 [150 to 321]</td><td>378 [263 to 521]</td></tr><tr><td>Nadir CD4 T-cell count in cells/μL</td><td>NA</td><td>209 [120 to 302]</td><td>118.5 [68 to 196]</td></tr><tr><td>ART duration (months)</td><td>NA</td><td>NA</td><td>56 [31 to 68]</td></tr><tr><td>Protease inhibitor use</td><td>NA</td><td>NA</td><td>18 (12.0%)</td></tr></table> |
c2e90abecc85b8a187fba02cdff32aa3705e8c047d18ffe346c56d28566de159.png | complex | <table><tr><td colspan="2"></td><td><i>N</i></td><td>Mean ± SD</td><td>Median</td><td>IQR</td><td>Range</td><td>β ± SE (p)</td></tr><tr><td rowspan="2">a)</td><td>Persisted to 2<sup>nd</sup> year</td><td>23</td><td>0·110 ± 0·068</td><td>0·105</td><td>0·061–0·139</td><td>0·026–0·308</td><td rowspan="2">2·9 ± 3·7 (0·44)</td></tr><tr><td>Did not persist</td><td>80</td><td>0·098 ± 0·060</td><td>0·089</td><td>0·065–0·117</td><td>0·000–0·301</td></tr><tr><td rowspan="2">b)</td><td>Both adults survived</td><td>42</td><td>0·093 ± 0·067</td><td>0·082</td><td>0·048–0·117</td><td>0·000–0·308</td><td rowspan="2">−3·7 ± 3·4 (0·29)</td></tr><tr><td>One or both adults died</td><td>61</td><td>0·106 ± 0·058</td><td>0·097</td><td>0·069–0·118</td><td>0·000–0·301</td></tr><tr><td rowspan="2">c)</td><td>Did not divorce</td><td>23</td><td>0·110 ± 0·068</td><td>0·105</td><td>0·061–0·139</td><td>0·026–0·308</td><td rowspan="2">−9·9 ± 5·8 (0·09)</td></tr><tr><td>Divorced</td><td>19</td><td>0·073 ± 0·061</td><td>0·081</td><td>0·033–0·096</td><td>0·000–0·254</td></tr><tr><td rowspan="2">d)</td><td>Persisted to 3<sup>rd</sup> year</td><td>5</td><td>0·159 ± 0·026</td><td>0·147</td><td>0·142–0·169</td><td>0·136–0·200</td><td rowspan="2"><i>t</i> = −5·9 (0·001)</td></tr><tr><td>Did not persist</td><td>11</td><td>0·071 ± 0·031</td><td>0·067</td><td>0·047–0·093</td><td>0·031–0·117</td></tr><tr><td rowspan="2">e)</td><td>Persisted to next year</td><td>28</td><td>0·118 ± 0·065</td><td>0·115</td><td>0·067–0·147</td><td>0·026–0·308</td><td rowspan="2">6·2 ± 3·4 (0·08)</td></tr><tr><td>Did not persist</td><td>91</td><td>0·095 ± 0·058</td><td>0·086</td><td>0·061–0·115</td><td>0·000–0·301</td></tr></table> |
a977a675cf70d54249794db2cfc9d40d3c7c00695423e815f078385e71238ef9.png | simple | <table><tr><td></td><td>Mean (mm)</td><td>Standard Deviation (mm)</td></tr><tr><td>Study I</td><td>0.43</td><td>3.54</td></tr><tr><td>Study II</td><td>‐1.77</td><td>5.23</td></tr></table> |
d1134fd1efe1c89edc6e4a9afc29798a41996aff10689b482269fe6a13654204.png | simple | <table><tr><td>Variable</td><td>Event</td><td>PYs</td><td>Rate</td><td>Crude HR (95% CI)</td><td>Adjusted HR (95% CI)</td></tr><tr><td>Comparison cohort</td><td>191</td><td>44535</td><td>42.89</td><td>ref</td><td>ref</td></tr><tr><td>OSA without treatment</td><td>62</td><td>6018</td><td>103.02</td><td>2.41 (1.81–3.21)</td><td>2.15 (1.60–2.88)</td></tr><tr><td>OSA with surgery only</td><td>7</td><td>1407</td><td>49.75</td><td>1.15 (0.54–2.45)</td><td>1.53 (0.72–3.29)</td></tr><tr><td> With pharyngeal surgery</td><td>5</td><td>858</td><td>58.25</td><td>1.34 (0.55–3.27)</td><td>1.86 (0.76–4.56)</td></tr><tr><td> With nasal surgery</td><td>2</td><td>549</td><td>36.45</td><td>0.84 (0.21–3.38)</td><td>1.14 (0.28–4.62)</td></tr><tr><td>OSA with CPAP only</td><td>27</td><td>2712</td><td>99.55</td><td>2.34 (1.56–3.50)</td><td>1.65 (1.09–2.49)</td></tr><tr><td>OSA with multiple modality</td><td>5</td><td>972</td><td>51.46</td><td>1.16 (0.48–2.82)</td><td>1.25 (0.51–3.04)</td></tr></table> |
d073b9d38365dbea97684baae06f017b077f40e19b893e1d8b1cd08390c1c3ba.png | complex | <table><tr><td>Cox regression</td><td colspan="2">Crude analysis</td><td colspan="2">Adjusted analysis</td></tr><tr><td>Variable</td><td><i>RR</i></td><td>95% CI</td><td><i>RR</i></td><td>95% CI</td></tr><tr><td><i>Sex</i></td><td></td><td></td><td></td><td></td></tr><tr><td> Female</td><td>1</td><td></td><td>1</td><td></td></tr><tr><td> Male</td><td>1.48</td><td>0.80-2.74</td><td>1.50</td><td>0.81-2.79</td></tr><tr><td><i>Age</i></td><td>1.03*</td><td>1.01-1.05</td><td>1.03*</td><td>1.01-1.05</td></tr><tr><td><i>Suicide prevention team</i></td><td></td><td></td><td></td><td></td></tr><tr><td> No</td><td>1</td><td></td><td>1</td><td></td></tr><tr><td> Yes</td><td>0.76</td><td>0.41-1.39</td><td>0.85</td><td>0.46-1.57</td></tr><tr><td><i>Previous attempt</i></td><td></td><td></td><td></td><td></td></tr><tr><td> No</td><td>1</td><td></td><td></td><td></td></tr><tr><td> One</td><td>1.56</td><td>0.72-3.39</td><td></td><td></td></tr><tr><td> Several</td><td>0.93</td><td>0.47-3.95</td><td></td><td></td></tr><tr><td><i>Aftercare referrals</i></td><td></td><td></td><td></td><td></td></tr><tr><td> Others</td><td>1</td><td></td><td>1</td><td></td></tr><tr><td> Out-patient</td><td>0.72</td><td>0.38-1.35</td><td>0.88</td><td>0.64-1.21</td></tr><tr><td><i>Alcohol misuse</i></td><td></td><td></td><td></td><td></td></tr><tr><td> No</td><td>1</td><td></td><td></td><td></td></tr><tr><td> Yes</td><td>1.07</td><td>0.51-2.23</td><td></td><td></td></tr><tr><td><i>Marital status</i></td><td></td><td></td><td></td><td></td></tr><tr><td> Others</td><td>1</td><td></td><td></td><td></td></tr><tr><td> Married/cohabitant</td><td>1.28</td><td>0.67-2.48</td><td></td><td></td></tr><tr><td><i>Employment</i></td><td></td><td></td><td></td><td></td></tr><tr><td> Employed</td><td>1</td><td></td><td></td><td></td></tr><tr><td> Unemployed/disabled</td><td>1.48</td><td>0.57-3.81</td><td></td><td></td></tr><tr><td> Student/pupil</td><td>0.57</td><td>0.16-2.05</td><td></td><td></td></tr><tr><td> Others</td><td>2.82*</td><td>1.19-6.66</td><td></td><td></td></tr></table> |
d93288de5ac4a75e1247607ec90b979a5ba54914b5b73cbdbe39776461cc94a0.png | complex | <table><tr><td colspan="2"><underline>TOP10 with pLC-T4LysHeat</underline></td></tr><tr><td>Lysis entity in exponential phase [%]</td><td>73 ± 0.3</td></tr><tr><td>Lysis delay after induction [min]</td><td>55</td></tr><tr><td>Doubling time [min]</td><td>66.1 ± 1.7</td></tr><tr><td>Doubling time of negative control [min]</td><td>65.9 ± 0.6</td></tr></table> |
a3f85133fa8a27004872621fc496947a9050f3ba6b71f69936f307c596bdb382.png | complex | <table><tr><td rowspan="2">Effects (% Substitution)</td><td colspan="2">Peak 1 (cP)</td><td colspan="2">Trough 1 (Nm)</td><td colspan="2">Break Down</td><td colspan="2">Final Visc <sup>3</sup> (cP)</td><td colspan="2">Setback (cP)</td><td colspan="2">Peak Time (min)</td><td colspan="2">Pasting Temp (°C)</td></tr><tr><td>Mean</td><td>SD <sup>2</sup></td><td>Mean</td><td>SD</td><td>Mean</td><td>SD</td><td>Mean</td><td>SD</td><td>Mean</td><td>SD</td><td>Mean</td><td>SD</td><td>Mean</td><td>SD</td></tr><tr><td>DDGS (%)</td><td colspan="2"></td><td colspan="2"></td><td colspan="2"></td><td colspan="2"></td><td colspan="2"></td><td colspan="2"></td><td colspan="2"></td></tr><tr><td>0</td><td>1532.0 <sup>a</sup></td><td>309.27</td><td>839.33 <sup>a</sup></td><td>360.90</td><td>692.66 <sup>a</sup></td><td>91.41</td><td>3243.83 <sup>a</sup></td><td>1968.38</td><td>2404.50 <sup>a</sup></td><td>1648.26</td><td>5.93 <sup>a</sup></td><td>0.56</td><td>86.13 <sup>a</sup></td><td>10.18</td></tr><tr><td>10</td><td>1208.17 <sup>b</sup></td><td>133.12</td><td>613.33 <sup>b</sup></td><td>181.97</td><td>594.83 <sup>b</sup></td><td>56.79</td><td>2152.50 <sup>b</sup></td><td>959.03</td><td>1539.17 <sup>b</sup></td><td>785.28</td><td>5.53 <sup>b</sup></td><td>0.29</td><td>85.21 <sup>a</sup></td><td>8.59</td></tr><tr><td>20</td><td>1017.50 <sup>b</sup></td><td>72.70</td><td>548.83 <sup>b</sup></td><td>23.49</td><td>468.66 <sup>c</sup></td><td>65.91</td><td>1561.00 <sup>b</sup></td><td>322.52</td><td>1012.17 <sup>b</sup></td><td>317.90</td><td>5.33 <sup>b</sup></td><td>0.04</td><td>88.36 <sup>a</sup></td><td>1.77</td></tr><tr><td>SSL (%)</td><td colspan="2"></td><td colspan="2"></td><td colspan="2"></td><td colspan="2"></td><td colspan="2"></td><td colspan="2"></td><td colspan="2"></td></tr><tr><td>0</td><td>1121.67 <sup>b</sup></td><td>71.48</td><td>474.33 <sup>b</sup></td><td>59.53</td><td>647.33 <sup>a</sup></td><td>98.98</td><td>993.50 <sup>b</sup></td><td>250.70</td><td>519.16 <sup>b</sup></td><td>233.97</td><td>5.25 <sup>b</sup></td><td>0.05</td><td>79.15 <sup>b</sup></td><td>8.99</td></tr><tr><td>2</td><td>1233.33 <sup>ab</sup></td><td>221.02</td><td>661.33 <sup>ab</sup></td><td>163.97</td><td>572.00 <sup>b</sup></td><td>106.28</td><td>2676.50 <sup>a</sup></td><td>1089.27</td><td>2015.17 <sup>a</sup></td><td>935.38</td><td>5.65 <sup>a</sup></td><td>0.35</td><td>89.30 <sup>a</sup></td><td>0.75</td></tr><tr><td>5</td><td>1402.67 <sup>a</sup></td><td>423.11</td><td>865.83 <sup>a</sup></td><td>311.94</td><td>536.83 <sup>b</sup></td><td>132.10</td><td>3287.33 <sup>a</sup></td><td>1418.14</td><td>2421.50 <sup>a</sup></td><td>1132.29</td><td>5.88 <sup>a</sup></td><td>0.51</td><td>91.25 <sup>a</sup></td><td>2.02</td></tr></table> |
e87bba5267499998e22dc7e6b826adea9c0d3ff1a843f8ea24b55db5dea6fd86.png | simple | <table><tr><td>Gene</td><td>Primer sequence</td></tr><tr><td>Collagen II</td><td>Forward primer 5′‐GCTCCCAGAACATCACCTACCA‐3′Reverse primer 5′‐ACAGTCTTGCCCCACTTACCG‐3′</td></tr><tr><td>Aggrecan</td><td>Forward primer 5′‐AGGTCGTGGTGAAAGGTGTTGTG‐3′Reverse primer 5′‐TGGTGGAAGCCATCCTCGTAG‐3′</td></tr><tr><td>Sox‐9</td><td>Forward primer 5′‐CGAGCCGGACCTCAAGAAG‐3′Reverse primer 5′‐ GCACCAGCGTCCAGTCGTA‐3′</td></tr><tr><td>Collagen X</td><td>Forward primer 5′‐GCCCTTCTGCTGCTAGTGTCTTT‐3′Reverse primer 5′‐TGTGTCTTGGTGTTGGGTTGTG‐3′</td></tr><tr><td>GAPDH</td><td>Forward primer 5′‐AAGGTCGGAGTGAACGGATTTG‐3′Reverse primer 5′‐CGTGGGTGGAATCATACTGGAAC‐3′</td></tr></table> |
b5060c7db73e921cfbb38edc42c0541cfebc0ac7670f6c4def7f531b3c289e2b.png | simple | <table><tr><td>Plant species</td><td>Degree of inhibition</td></tr><tr><td><i>Andrographis paniculata</i></td><td>+++</td></tr><tr><td><i>Momordica charantia</i></td><td>++</td></tr><tr><td><i>Cymbopogn citratus</i></td><td>+</td></tr><tr><td><i>Ocimum sanctum</i></td><td>+</td></tr><tr><td><i>Citrus limon</i></td><td>-</td></tr><tr><td><i>Pelargonium citrosum</i></td><td>-</td></tr></table> |
a16cd6aa272f9928b6da8825cf8d56e473e9419a97da1e2ab52f06a4bafc4b11.png | complex | <table><tr><td>HCV Genotype</td><td colspan="2">Modified Multiplex PCR Method (Genotype Specific Primers)</td><td colspan="2">INNO-LiPA HCV II (Line Probe Assay)</td></tr><tr><td></td><td>Isolates, No.</td><td>Percentage</td><td>Isolates, No.</td><td>Percentage</td></tr><tr><td>1a</td><td>1</td><td>1.37</td><td>1</td><td>1.37</td></tr><tr><td>1b</td><td>1</td><td>1.37</td><td>1</td><td>1.37</td></tr><tr><td>3a</td><td>3</td><td>4.11</td><td>3</td><td>4.11</td></tr><tr><td>4</td><td>65</td><td>89.04</td><td>38</td><td>52.05</td></tr><tr><td>4a</td><td>-</td><td>-</td><td>2</td><td>2.74</td></tr><tr><td>4c/4d</td><td>-</td><td>-</td><td>18</td><td>24.66</td></tr><tr><td>4e</td><td>-</td><td>-</td><td>5</td><td>6.85</td></tr><tr><td>4h</td><td>-</td><td>-</td><td>4</td><td>5.48</td></tr><tr><td>Not Genotyped</td><td>3</td><td>4.11</td><td>1</td><td>1.37</td></tr><tr><td>Total</td><td>73</td><td>100</td><td>73</td><td>100</td></tr></table> |
437d2e2d5d21cd5f910ad2eeaf4abe5ea0ea71055e90752e626e61fd9b5882f7.png | complex | <table><tr><td>Characteristics</td><td>Frequency</td><td>Percentage</td></tr><tr><td colspan="3">Sex</td></tr><tr><td> Male</td><td>482</td><td>53.8</td></tr><tr><td> Female</td><td>414</td><td>46.2</td></tr><tr><td colspan="3">Religion</td></tr><tr><td> Christianity</td><td>888</td><td>99.1</td></tr><tr><td> Islam</td><td>6</td><td>0.7</td></tr><tr><td> Traditional African Religion</td><td>2</td><td>0.2</td></tr><tr><td colspan="3">Parental Background</td></tr><tr><td> Father dead</td><td>80</td><td>8.9</td></tr><tr><td> Mother dead</td><td>32</td><td>3.6</td></tr><tr><td> One or both parents dead</td><td>106</td><td>11.8</td></tr><tr><td> Parents alive but divorced</td><td>23</td><td>2.6</td></tr><tr><td> Parents deprivation</td><td>129</td><td>14.4</td></tr><tr><td> Father smokes</td><td>62</td><td>6.9</td></tr><tr><td> Mother smokes</td><td>3</td><td>0.3</td></tr><tr><td> Father takes alcohol</td><td>306</td><td>34.2</td></tr><tr><td> Mother takes alcohol</td><td>130</td><td>14.5</td></tr></table> |
041b4619697c8dfa0a851cde04ce29a16d6b3ba003cbecbffc01ffea515aa627.png | complex | <table><tr><td>Sample</td><td colspan="3">Wild type CHO-S crude protein extract</td><td colspan="3">pcDNA: <i>trp-2</i><sub><i>1-472</i></sub><i>-cA</i> transfected CHO-S cell crude protein extract</td></tr><tr><td>Replicates</td><td>1</td><td>2</td><td>3</td><td>1</td><td>2</td><td>3</td></tr><tr><td>0 min</td><td>0.203</td><td>0.205</td><td>0.202</td><td>0.205</td><td>0.208</td><td>0.206</td></tr><tr><td>5 mins</td><td>0.196</td><td>0.199</td><td>0.194</td><td>0.173</td><td>0.179</td><td>0.175</td></tr><tr><td>10 mins</td><td>0.184</td><td>0.188</td><td>0.180</td><td>0.140</td><td>0.147</td><td>0.143</td></tr><tr><td>15 mins</td><td>0.179</td><td>0.182</td><td>0.176</td><td>0.101</td><td>0.106</td><td>0.104</td></tr><tr><td>20 mins</td><td>0.170</td><td>0.173</td><td>0.168</td><td>0.093</td><td>0.098</td><td>0.095</td></tr></table> |
3a06679ac46b86a6deb063bd49020075e5da2ebe8ec8473f6ac3154ead8dd21e.png | complex | <table><tr><td>Parameters</td><td>Hazard ratio</td><td>95% confidence interval</td><td>P value</td></tr><tr><td colspan="4">5-year-DFS</td></tr><tr><td>EZH2</td><td>2.287</td><td>1.137-4.602</td><td>0.020</td></tr><tr><td>pT</td><td>2.244</td><td>1.076-4.678</td><td>0.013</td></tr><tr><td>pN</td><td>2.532</td><td>1.292-4.961</td><td>0.007</td></tr><tr><td>5-year-OS</td><td></td><td></td><td></td></tr><tr><td>EZH2</td><td>2.182</td><td>0.940-5.064</td><td>0.069</td></tr><tr><td>pT</td><td>2.395</td><td>0.997-5.365</td><td>0.051</td></tr><tr><td>pN</td><td>2.471</td><td>1.138-5.364</td><td>0.022</td></tr></table> |
a7180054a0946746b05092e3c266b62db9e6aeba4f7fda1343f5bd3cc1c2a91d.png | complex | <table><tr><td>Variable</td><td></td><td>Men (<i>n</i> = 21)</td><td>Women (<i>n</i> = 19)</td><td>Total (<i>n</i> = 40)</td></tr><tr><td rowspan="2">Glucose (mg/dL)</td><td>Week 0</td><td>103.3 ± 5.0</td><td>96.4 ± 3.3</td><td>99.8 ± 3.0</td></tr><tr><td>Week 12 <sup>a</sup></td><td>91.3 ± 2.1</td><td>89.8 ± 2.3</td><td>90.5 ± 1.5</td></tr><tr><td rowspan="2">Insulin (μU/mL)</td><td>Week 0</td><td>9.2 ± 1.1</td><td>6.0 ± 0.5</td><td>7.6 ± 0.7</td></tr><tr><td>Week 12 <sup>a</sup></td><td>5.5 ± 0.8</td><td>3.5 ± 0.3</td><td>4.5 ± 0.5</td></tr><tr><td rowspan="2">Leptin (ng/mL)</td><td>Week 0</td><td>13.6 ± 1.7</td><td>84.7 ± 17.7</td><td>45.4 ± 9.8</td></tr><tr><td>Week 12 <sup>a</sup></td><td>6.6 ± 1.3</td><td>22.9 ± 3.5</td><td>13.9 ± 2.1</td></tr><tr><td rowspan="2">Adiponectin (ng/mL)</td><td>Week 0</td><td>16.1 ± 2.1</td><td>27.8 ± 5.3</td><td>21.7 ± 2.9</td></tr><tr><td>Week 12</td><td>15.7 ± 1.6</td><td>27.3 ± 4.3</td><td>21.2 ± 2.3</td></tr></table> |
ef75d19174432833e30058da061237a6dbe909ce20fc029db7f574db55e4ea9f.png | complex | <table><tr><td rowspan="2">Mixture</td><td colspan="5">Compressive Strength (MPa) *</td></tr><tr><td>3 Days</td><td>7 Days</td><td>14 Days</td><td>28 Days</td><td>90 Days</td></tr><tr><td>C-0.45-N</td><td>30.74 <i>0.77</i></td><td>41.93 <i>0.67</i></td><td>49.17 <i>1.40</i></td><td>56.93 <i>0.81</i></td><td>65.98 <i>0.92</i></td></tr><tr><td>C-0.45-H</td><td>34.79 <i>0.63</i></td><td>45.82 <i>0.89</i></td><td>54.43 <i>0.17</i></td><td>61.72 <i>1.67</i></td><td>69.73 <i>0.42</i></td></tr><tr><td>C-0.45-SCM</td><td>40.76 <i>0.68</i></td><td>48.95 <i>0.16</i></td><td>57.28 <i>0.81</i></td><td>64.43 <i>1.85</i></td><td>73.48 <i>1.17</i></td></tr><tr><td>10FA-0.45-N</td><td>31.77 <i>2.41</i></td><td>43.44 <i>0.81</i></td><td>50.50 <i>0.40</i></td><td>58.08 <i>1.15</i></td><td>67.13 <i>0.94</i></td></tr><tr><td>10FA-0.45-H</td><td>33.68 <i>0.25</i></td><td>46.45 <i>1.27</i></td><td>53.45 <i>0.20</i></td><td>60.51 <i>1.54</i></td><td>69.33 <i>1.27</i></td></tr><tr><td>10FA-0.45-SCM</td><td>35.83 <i>0.95</i></td><td>49.26 <i>0.39</i></td><td>56.17 <i>0.85</i></td><td>62.48 <i>0.67</i></td><td>71.53 <i>1.31</i></td></tr><tr><td>20FA-0.45-N</td><td>21.33 <i>0.16</i></td><td>29.21 <i>0.55</i></td><td>35.88 <i>0.69</i></td><td>43.24 <i>0.10</i></td><td>53.29 <i>1.14</i></td></tr><tr><td>20FA-0.45-H</td><td>23.73 <i>0.47</i></td><td>32.64 <i>1.40</i></td><td>40.51 <i>0.32</i></td><td>49.11 <i>1.37</i></td><td>56.98 <i>0.87</i></td></tr><tr><td>20FA-0.45-SCM</td><td>29.21 <i>0.75</i></td><td>35.07 <i>0.29</i></td><td>42.77 <i>1.83</i></td><td>52.62 <i>0.58</i></td><td>61.67 <i>1.24</i></td></tr><tr><td>40FA-0.45-N</td><td>14.25 <i>0.26</i></td><td>21.68 <i>0.34</i></td><td>27.11 <i>0.32</i></td><td>31.42 1.16</td><td>41.47 <i>0.83</i></td></tr><tr><td>40FA-0.45-H</td><td>16.50 <i>0.50</i></td><td>22.96 <i>0.31</i></td><td>28.96 <i>2.01</i></td><td>33.71 <i>0.77</i></td><td>44.18 <i>1.23</i></td></tr><tr><td>40FA-0.45-SCM</td><td>18.56 <i>0.23</i></td><td>25.39 <i>1.25</i></td><td>30.69 <i>0.37</i></td><td>36.83 <i>1.43</i></td><td>46.88 <i>0.87</i></td></tr><tr><td>60FA-0.45-N</td><td>13.18 <i>1.15</i></td><td>19.78 <i>0.93</i></td><td>26.17 <i>0.82</i></td><td>30.87 <i>1.34</i></td><td>40.24 <i>0.52</i></td></tr><tr><td>60FA-0.45-H</td><td>15.65 <i>0.78</i></td><td>21.29 <i>0.64</i></td><td>27.82 <i>1.04</i></td><td>32.19 <i>0.90</i></td><td>42.78 <i>0.89</i></td></tr><tr><td>60FA-0.45-SCM</td><td>17.24 <i>1.39</i></td><td>24.61 <i>0.75</i></td><td>29.94 <i>0.44</i></td><td>35.61 <i>0.32</i></td><td>45.31 <i>0.59</i></td></tr></table> |
2495d649d7b25b964991797f45e43c9d48ee97c4066b6018414be9b9c77f1a14.png | complex | <table><tr><td rowspan="2">Groups</td><td rowspan="2">Dose (TCID50) 1 mL</td><td colspan="9">Survival rate (day post infection)</td><td rowspan="2">Mortality (%)</td></tr><tr><td>6</td><td>7</td><td>8</td><td>9</td><td>10</td><td>11</td><td>12</td><td>13</td><td>14</td></tr><tr><td>PRV FJ-2012</td><td>10<sup>6</sup></td><td>4/4</td><td>4/4</td><td>3/4</td><td>3/4</td><td>2/4</td><td>2/4</td><td>1/4</td><td>1/4</td><td>0/4</td><td>100</td></tr><tr><td>Cohabitation</td><td>DMEM</td><td>2/2</td><td>2/2</td><td>2/2</td><td>2/2</td><td>2/2</td><td>2/2</td><td>1/2</td><td>1/2</td><td>1/2</td><td>50</td></tr><tr><td>Control</td><td>DMEM</td><td>4/4</td><td>4/4</td><td>4/4</td><td>4/4</td><td>4/4</td><td>4/4</td><td>4/4</td><td>4/4</td><td>4/4</td><td>0</td></tr></table> |
fdb7954d71f521fe84bf28ee5c31d4d09a9b3cc9b2931b1d08bf8078ca9aee65.png | simple | <table><tr><td>Supplementary addition of L- proline (mM)</td><td>0</td><td>1</td><td>2</td><td>4</td><td>8</td><td>12</td></tr><tr><td>Hyp (g/L)</td><td>2.28</td><td>2.81</td><td>3.25</td><td>6.72</td><td>5.56</td><td>6.32</td></tr></table> |
f8fece1034fbae35d4988c512295c4e52061040687f81fc367691c0723c11f2f.png | complex | <table><tr><td rowspan="2">Treatment</td><td colspan="2">Open dentinal tubules (N/mm<sup>2</sup>) (N=20)</td><td colspan="2">Diameter of tubules (μm) (N=20)</td></tr><tr><td>Old root </td><td>Young root </td><td>Old root </td><td>Young root </td></tr><tr><td>Citric acid</td><td>122 (14) </td><td>152 (19) </td><td>2.0 (0.1) </td><td>1.7 (0.2) </td></tr><tr><td>EDTA</td><td>161 (22) </td><td>140 (17) </td><td>2.3 (0.1) </td><td>1.7 (0.2) <sup>a</sup></td></tr><tr><td>Control</td><td>147 (10) </td><td>159 (24) </td><td>1.6 (0.2) </td><td>1.9 (0.2) </td></tr></table> |
1b2e55d6bedda37626738e6b215c545b3af16336ed4ceccf0f528592ac53c7b6.png | simple | <table><tr><td>SOUND CATEGORY</td><td>DESCRIPTION</td></tr><tr><td>Mouth</td><td>Crunching a hard candy</td></tr><tr><td></td><td>Kissing</td></tr><tr><td></td><td>Gargling</td></tr><tr><td></td><td>Crunching chips</td></tr><tr><td></td><td>Finishing a beverage with a straw</td></tr><tr><td>Hand</td><td>Ripping a sheet of paper</td></tr><tr><td></td><td>Unrolling scotch tape</td></tr><tr><td></td><td>Zipping a zipper</td></tr><tr><td></td><td>Opening a soda can</td></tr><tr><td></td><td>Crushing a soda can</td></tr><tr><td>Environmental</td><td>Train passing by</td></tr><tr><td></td><td>Howling wind</td></tr><tr><td></td><td>Waves breaking on the shore</td></tr><tr><td></td><td>Electric discharge</td></tr><tr><td></td><td>Water dripping</td></tr><tr><td>Hand control (Fuzzy)</td><td>Crumple can</td></tr><tr><td></td><td>Open can</td></tr><tr><td></td><td>Zip</td></tr><tr><td></td><td>Scotch</td></tr><tr><td></td><td>Paper</td></tr><tr><td>Mouth control (Fuzzy)</td><td>Kiss</td></tr><tr><td></td><td>Candy</td></tr><tr><td></td><td>Chips</td></tr><tr><td></td><td>Gargle</td></tr><tr><td></td><td>Straw</td></tr></table> |
6da5c2e2c89fa59661c9e439af6549b0c485b558b3f8f6b8a71ec53d4e877912.png | simple | <table><tr><td>DNA sequence</td><td>A</td><td>T</td><td>G</td><td>C</td><td>G</td><td>A</td><td>C</td><td>C</td><td>C</td><td>T...</td></tr><tr><td><i>x</i><sub><i>A</i></sub>(<i>k</i>):</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td><i>x</i><sub><i>C</i></sub>(<i>k</i>):</td><td>0</td><td>0</td><td>0</td><td>1</td><td>0</td><td>0</td><td>1</td><td>1</td><td>1</td><td>0</td></tr><tr><td><i>x</i><sub><i>G</i></sub>(<i>k</i>):</td><td>0</td><td>0</td><td>1</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td><i>x</i><sub><i>T</i></sub>(<i>k</i>):</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1</td></tr></table> |
4ab9d0e98022c5e4078b1216ce15b76556bc0815656a0a3abf51d805c3076a22.png | complex | <table><tr><td>Antigen</td><td colspan="2">Antibody</td><td>Crude IRR (95%CI)</td><td>P-value</td><td>Age-adjusted IRR</td><td>P-value</td></tr><tr><td>MSP3</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>IgG2*</td><td>(coded as log(2))</td><td>0.74 (0.57, 0.98)</td><td>0.04</td><td>0.85 (0.63, 1.15)</td><td>0.29</td></tr><tr><td></td><td>IgG4</td><td>< detection limit</td><td>1</td><td>0.01</td><td>1</td><td>0.20</td></tr><tr><td></td><td></td><td>< median</td><td>0.45 (0.21, 0.95)</td><td></td><td>0.56 (0.26, 1.19)</td><td></td></tr><tr><td></td><td></td><td>≥ median</td><td>0.47 (0.28, 0.79)</td><td></td><td>0.68 (0.40, 1.15)</td><td></td></tr><tr><td>MSP1<sub>19</sub></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>IgG2*</td><td>(coded as log(2))</td><td>0.62 (0.45, 0.86)</td><td>< 0.01</td><td>0.836 (0.606, 1.157)</td><td>0.275</td></tr><tr><td></td><td>IgG4*</td><td>(coded as log(2))</td><td>1.07 (0.95, 1.21)</td><td>0.25</td><td>0.838 (0.608, 1.159)</td><td>0.278</td></tr><tr><td>GLURP</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>IgG2*</td><td>(coded as log(2))</td><td>0.65 (0.49, 0.86)</td><td>< 0.01</td><td>0.79 (0.58, 1.08)</td><td>0.13</td></tr><tr><td></td><td>IgG4*</td><td>(coded as log(2))</td><td>0.94 (0.81, 1.08)</td><td>0.37</td><td>1.01 (0.87, 1.16)</td><td>0.94</td></tr><tr><td>AMA1</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>IgG2</td><td>< detection limit</td><td>1</td><td>0.18</td><td>1</td><td>0.54</td></tr><tr><td></td><td></td><td>< median</td><td>1.80 (0.86, 3.78)</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>≥ median</td><td>1.78 (0.90, 3.51)</td><td></td><td></td><td></td></tr><tr><td></td><td>IgG4</td><td>< detection limit</td><td>1</td><td>0.19</td><td>1</td><td>0.54</td></tr><tr><td></td><td></td><td>< median</td><td>0.96 (0.47, 1.93)</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>≥ median</td><td>0.62 (0.36, 1.07)</td><td></td><td></td><td></td></tr></table> |
67dc30b63d5d5d9e0d2430a57b54465ad9ddef64ed544397330a751bd0d3f3c3.png | simple | <table><tr><td></td><td>CEER</td><td>Reverse Phase Protein Array</td><td>PhosphoFlow</td><td>ELISA</td></tr><tr><td>Sample Protein Requirement</td><td>Native proteins</td><td>Denatured proteins</td><td>Fixed proteins</td><td>Native or Fixed proteins</td></tr><tr><td>Minimum Cell Requirement (Assay Sensitivity)</td><td>1 cell</td><td>2500~15000 cells</td><td>1 × 10<sup>4</sup>~1 × 10<sup>6 </sup>cells</td><td>150 to 300 cells</td></tr><tr><td>Multiplex Format</td><td>One sample, multiple analytes</td><td>Multiple samples, one analyte</td><td>One sample, multiple analytes (limited)</td><td>Multiple samples, one analyte</td></tr><tr><td>Assay Specificity</td><td>• High</td><td>• Low</td><td>• Low</td><td>• Medium</td></tr><tr><td>Advantages of Assay</td><td>• Simultaneous analysis of multiple analytes (e.g. selected analytes of a signaling pathway) on a single sample.• Suitable for clinical samples of rare cells as well as limited solid tissue samples.</td><td>• Simultaneous analysis of multiple samples for a single analyte.• Suitable for samples of cells or solid tissue.</td><td>• Detection of target molecules within a cell population in one sample.• Suitable for blood sample analysis.</td><td>• High throughput.</td></tr><tr><td>Disadvantages of Assay</td><td>• Screening compatible antibody sets for each target.</td><td>• Need to print each sample; not suitable for applications in clinical samples from individual patients.• Cross reaction of detector antibody.</td><td>• Not suitable for rare cell analysis or solid tissue samples.• Requires a large number of cells.• Requires samples in single cell suspension, limiting its use.</td><td>• Low sensitivity requires large numbers of cells.• Not suitable for rare cell analysis.</td></tr></table> |
eac3b643a3f6d4b263d8bd1d4414ac09d799d2171d826e5330e684f767bbd3ac.png | simple | <table><tr><td></td><td>Sensitivity</td><td>Specificity</td><td>Positive Predictive Value</td><td>Negative Predictive Value</td></tr><tr><td>PF/other<sup>1</sup>(PF gametocytaemia considered negative for PF)</td><td>89.1[85.5-91.8]</td><td>97.6[96.5-98.4]</td><td>93.8[90.8-95.9]</td><td>95.2[94.2-96.8]</td></tr><tr><td>PF/other<sup>2</sup>(PF gametocytaemia considered positive for PF)</td><td>85.1[81.3-88.2]</td><td>96.1[94.7-97.2]</td><td>90.6[87.3-93.2]</td><td>93.6[91.9-95.0]</td></tr><tr><td>PF mono-infection<sup>1</sup>(PF gametocytaemia considered negative for PF)</td><td>95.6[87.7-98.5]</td><td>-</td><td>-</td><td>-</td></tr><tr><td>PF mono-infection<sup>2</sup>(PF gametocytaemia considered positive for PF)</td><td>86.7[79.9-91.4]</td><td>-</td><td>-</td><td>-</td></tr><tr><td>PV mono-infection<sup>1</sup>(PV gametocytaemia considered negative for PV)</td><td>91.0[86.5-94.1]</td><td>-</td><td>-</td><td>-</td></tr><tr><td>PV mono-infection<sup>2</sup>(PV gametocytaemia considered positive for PV)</td><td>88.4[83.7-91.9]</td><td>-</td><td>-</td><td>-</td></tr></table> |
70eae41057f2ca1244fd26c21d91de9723cfae7eabd4c1bdbad266513a6f92e8.png | simple | <table><tr><td>ORF</td><td>Gene</td><td>Identification</td><td>Genotype used in this study</td></tr><tr><td>F17A2.5</td><td><i>ceh-40</i></td><td>Homeodomain protein (<i>Extradenticle </i>ortholog)</td><td><i>ceh-40(ok740) </i>X</td></tr><tr><td>K10B4.6</td><td><i>cwn-1</i></td><td>Putative Wnt ligand</td><td><i>cwn-1(ok546) </i>II</td></tr><tr><td>D1081.2</td><td><i>unc-120</i></td><td>MADS domain TF</td><td><i>unc-120(st364) </i>I</td></tr><tr><td>B0304.1</td><td><i>hlh-1</i></td><td>bHLH TF</td><td><i>hlh-1(cc561) </i>II</td></tr><tr><td>C44C10.8</td><td><i>hnd-1</i></td><td>Hand bHLH TF</td><td><i>hnd-1(q740) </i>X</td></tr><tr><td>F35G12.6</td><td><i>mab-21</i></td><td>Highly conserved novel protein</td><td><i>mab-21(bx53)</i>III; <i>him-5(e1490)</i>V</td></tr><tr><td>F11C1.6</td><td><i>nhr-25</i></td><td>Nuclear hormone receptor</td><td>+/szT1 [<i>lon-2(e678)</i>] I; <i>nhr-25(jm2389)/</i>szT1 X</td></tr><tr><td>Y75B8A.2</td><td><i>nob-1</i></td><td>Homeodomain TF (posterior Hox paralog)</td><td><i>nob-1(ct223) dpy-18(e364) unc-25(e156) </i>III; eDp6 (III;f)</td></tr><tr><td>K02B9.4</td><td><i>elt-3</i></td><td>GATA TF</td><td><i>elt-3(gk121) </i>X</td></tr><tr><td>T07C4.2</td><td><i>tbx-8</i></td><td>T-box TF (Brachyury)</td><td><i>tbx-8(ok656) </i>III</td></tr><tr><td>M142.4</td><td><i>vab-7</i></td><td>Homeobox TF (even-skipped subfamily)</td><td><i>vab-7(e1562) </i>III</td></tr><tr><td>T07C4.6</td><td><i>tbx-9</i></td><td>T-box TF (Brachyury)</td><td>Mutant not available</td></tr><tr><td>C55C2.1</td><td></td><td>Zinc-finger TF</td><td>Mutant not available</td></tr><tr><td>C38D4.6</td><td><i>pal-1</i></td><td>Homeobox TF (cad subfamily)</td><td><i>pal-1(ct224) dpy-17(e164) ncl-1(e1865) unc-36(e251</i>) III; sDp3(f:III); <i>lin-2(e1309) </i>X</td></tr><tr><td>W09C2.1</td><td><i>elt-1</i></td><td>GATA TF</td><td><i>elt-1(zu180) unc-43(e408</i>)/<i>unc-24(e138) dpy-20(e1282) </i>IV</td></tr><tr><td>F18A1.2</td><td><i>lin-26</i></td><td>Zinc-finger TF</td><td><i>lin-26(n156) </i>II</td></tr><tr><td>T28F12.2</td><td><i>unc-62</i></td><td>Meis-class homeodomain (<i>Homothorax </i>ortholog)</td><td><i>unc-62(e644) </i>V</td></tr><tr><td>C28C12.7</td><td><i>spp-10</i></td><td>Predicted prosaposin</td><td>Mutant not available</td></tr><tr><td>R02D3.1</td><td></td><td>Dehydrogenase</td><td>Mutant not available</td></tr><tr><td>C09D4.2</td><td></td><td>Uncharacterized</td><td>Mutant not available</td></tr><tr><td>R07C3.11</td><td></td><td>Uncharacterized</td><td>Mutant not available</td></tr><tr><td>T22B7.3</td><td></td><td>Uncharacterized</td><td>Mutant not available</td></tr><tr><td>C46H11.2</td><td></td><td>Uncharacterized</td><td>Mutant not available</td></tr><tr><td>ZK1307.1</td><td></td><td>Uncharacterized</td><td>Mutant not available</td></tr><tr><td>C01G6.1</td><td><i>aqp-2</i></td><td>Aquaporin</td><td>Mutant not available</td></tr><tr><td>T27D12.1</td><td></td><td>Sodium/phosphate transporter</td><td>Mutant not available</td></tr></table> |
4a7a7321f00d60085cb9e795afddca720a6ab777144998290dfd65bf90acf62d.png | simple | <table><tr><td>Variables</td><td>R</td><td><i>p</i>-Value **</td></tr><tr><td>Socioeconomic</td><td></td><td></td></tr><tr><td>Age (years)</td><td>0.125</td><td>0.243</td></tr><tr><td>Schooling (years)</td><td>0.118</td><td>0.267</td></tr><tr><td>Per capita income (real)</td><td>−0.080</td><td>0.441</td></tr><tr><td>Water supply</td><td>0.061</td><td>0.565</td></tr><tr><td>Garbage collection</td><td>0.008</td><td>0.935</td></tr><tr><td>Sewer connect to the public network or existence of septic tank</td><td>0.162</td><td>0.128</td></tr><tr><td>Basic sanitation</td><td>0.226</td><td>0.033</td></tr><tr><td>Obstetric</td><td></td><td></td></tr><tr><td>Parity (number of pregnancies)</td><td>−0.125</td><td>0.243</td></tr><tr><td>Trimester at the time of blood collection</td><td>−0.317</td><td>0.002</td></tr><tr><td>Nutritional</td><td></td><td></td></tr><tr><td>Pre-gestational nutritional status (BMI/age) *</td><td>0.276</td><td>0.008</td></tr><tr><td>Gestational nutritional status (BMI) *</td><td>0.246</td><td>0.019</td></tr><tr><td>Infection (CRP ≥ 5 mg/L)</td><td>−0.068</td><td>0.527</td></tr><tr><td>Nutrient intake</td><td></td><td></td></tr><tr><td>Vitamin A (μg) *</td><td>0.046</td><td>0.666</td></tr><tr><td>Zinc (mg) *</td><td>0.048</td><td>0.654</td></tr><tr><td>Iron (mg) *</td><td>0.001</td><td>0.986</td></tr></table> |
c79ad6458404b28e44e62c2a10d454242c39bb1ebac5f41c9094be48b00afac2.png | simple | <table><tr><td>Summary of progress with IRS and ITNs</td><td>MIS 2006</td><td>MIS 2008</td><td>MIS 2010</td></tr><tr><td>Percentage of households receiving indoor residual spraying (IRS) in the previous 12 months among all households</td><td>9.5</td><td>14.9</td><td>23.1</td></tr><tr><td>Percentage of household members who slept under an ITN the previous night</td><td>19</td><td>34</td><td>42</td></tr><tr><td>Percentage of households covered by at least one ITN or recent IRS</td><td>43.2</td><td>68.3</td><td>72.9</td></tr><tr><td>Percentage of households covered by at least one ITN or recent IRS</td><td>43</td><td>68</td><td>73</td></tr><tr><td>Percentage of children ages 0–59 months who slept under an ITN the previous night</td><td>24</td><td>41</td><td>50</td></tr><tr><td>Percentage of children ages 0–59 months with malaria parasitaemia</td><td>22</td><td>10</td><td>16</td></tr></table> |
a8a07fae4b08f0ccff02f65ee375fa0f0b4eb66c17d4926b3131c22166b67d48.png | complex | <table><tr><td></td><td colspan="3">Factors</td></tr><tr><td>Self-assessment item</td><td>1</td><td>2</td><td>3</td></tr><tr><td>1) Obtain a medical history that is relevant to the patient's complaint</td><td>0.83</td><td></td><td></td></tr><tr><td>2) Perform a clinical examination that is targeted at the patient's chief complaint</td><td>0.72</td><td></td><td>0.39</td></tr><tr><td>3) Obtain a psychosocial history from the patient</td><td>0.67</td><td>0.33</td><td></td></tr><tr><td>4) Announce bad news (e.g., an unfavorable prognosis)</td><td>0.61</td><td>0.32</td><td></td></tr><tr><td>5) Make sure that an illiterate patient understands the treatment of his chronic disease (e.g., hypertension, depression, etc.)</td><td>0.52</td><td>0.43</td><td></td></tr><tr><td>6) Explain the reason for refusing an unjustified treatment or investigation to patient who requests it</td><td>0.52</td><td></td><td></td></tr><tr><td>7) Discuss advantages and risks of unconventional therapies with a patient who uses them</td><td></td><td>0.48</td><td></td></tr><tr><td>8) Discuss a patient's religious preferences and constraints regarding his treatment</td><td></td><td>0.73</td><td></td></tr><tr><td>9) Communicate the importance of medical treatment to a patient who believes that his illness is due to supernatural causes</td><td></td><td>0.65</td><td></td></tr><tr><td>10) Explore the migratory trajectory and possible traumatic experiences of an asylum seeker</td><td></td><td>0.68</td><td></td></tr><tr><td>11) Work effectively with a professional interpreter</td><td></td><td></td><td>0.65</td></tr><tr><td>12) Orient an immigrant patient without papers toward appropriate medical and social services</td><td></td><td>0.47</td><td>0.41</td></tr><tr><td>13) Perform a physical examination of a Muslim woman who wears a veil</td><td></td><td></td><td>0.79</td></tr><tr><td>14) Ask questions and give information to the husband of a patient, if she requests it</td><td></td><td></td><td>0.76</td></tr></table> |
0e5fa58216c06131acbcc20995885da3160007cdb3225776070b91c987ff22a6.png | simple | <table><tr><td>Group</td><td>nNOS activity (nmol/min/mg)</td><td>MDA nmol/g/wet tissue</td><td>GSH nmol/g/wet tissue</td></tr><tr><td>Control</td><td>0.604 ± 0.04</td><td>3.55 ± 0.20</td><td>1.68 ± 0.15</td></tr><tr><td>Cocaine</td><td>0.935 ± 0.14<sup>*</sup></td><td>4.65 ± 0.32<sup>*</sup></td><td>0.94 ± 0.10<sup>*</sup></td></tr><tr><td>7-NI</td><td>0.360 ± 0.07<sup>*</sup></td><td>3.50 ± 0.10</td><td>1.59 ± 0.10</td></tr><tr><td>7-NI + cocaine</td><td>0.535 ± 0.10<sup>+</sup></td><td>3.68 ± 0.15<sup>+</sup></td><td>1.55 ± 0.08<sup>+</sup></td></tr></table> |
55af6ae76a25d9bd53d90fa739e9c042881b4cda1e116a403093719b3350e123.png | complex | <table><tr><td>Parameters</td><td>Base-case</td><td>Range (min—max)</td><td>Reference</td></tr><tr><td>Thai birth cohort population</td><td>782,129</td><td>–</td><td>(19)</td></tr><tr><td>Incidence of haemophilus influenzae type b (Hib) meningitis in <1 year old</td><td>0.000137</td><td>0.000038–0.000236</td><td rowspan="2">(14, 20)</td></tr><tr><td>Incidence of Hib meningitis in ≥1 to <5 years old<sup>a</sup></td><td>0.000046</td><td>0.000038–0.000054</td></tr><tr><td>Incidence of Hib pneumonia in <5 years</td><td>0.000959</td><td>0.000266–0.001652</td><td>(21)<sup>b</sup></td></tr><tr><td>Incidence of Hib NPNM in population <5 years old</td><td>0.000025</td><td>0.000007–0.000043</td><td>(1)<sup>c</sup></td></tr><tr><td colspan="4">Case-fatality ratio of Hib meningitis</td></tr><tr><td>Estimate based on real-world evidence of national database (base-case analysis)</td><td>0.029</td><td>0.018–0.040</td><td>NHSO<sup>d</sup></td></tr><tr><td>Estimate from published article</td><td>0.099</td><td>0.049–0.149</td><td>(22)</td></tr><tr><td colspan="4">Case-fatality ratio of Hib pneumonia</td></tr><tr><td>Estimate based on real-world evidence of national database (base-case analysis)</td><td>0.019</td><td>0.012–0.026</td><td>NHSO<sup>d</sup></td></tr><tr><td>Estimate from published article</td><td>0.020</td><td>0.010–0.030</td><td>(1)</td></tr><tr><td colspan="4">Case-fatality ratio of Hib NPNM</td></tr><tr><td>Estimate based on real-world evidence of national database (base-case analysis)</td><td>0.050</td><td>0.022–0.078</td><td>NHSO<sup>d</sup></td></tr><tr><td>Estimate from published article</td><td>0.010</td><td>0.005–0.015</td><td>(1)</td></tr><tr><td>Probability of hearing loss after recovery from Hib meningitis</td><td>0.111</td><td>0.055–0.167</td><td></td></tr><tr><td>Probability of epilepsy after recovery from Hib meningitis</td><td>0.050</td><td>0.025–0.075</td><td>(23)</td></tr><tr><td>Probability of developmental deficit after recovery from Hib meningitis</td><td>0.083</td><td>0.041–0.125</td><td></td></tr><tr><td colspan="4">Risk ratio of mortality compared to general population</td></tr><tr><td>Hearing loss</td><td>1.075</td><td>1.010–1.140</td><td></td></tr><tr><td>Epilepsy</td><td>1.005</td><td>1.000–1.010</td><td>(24)</td></tr><tr><td>Developmental deficit</td><td>6.165</td><td>5.160–7.170</td><td></td></tr></table> |
50d45d0e1b6ccb3890ae28abb714eb91982520b5aae56700ececa50aa88f1d39.png | complex | <table><tr><td rowspan="2">Annual average</td><td colspan="3">Primary care utilisation</td><td colspan="3">95% confidence interval</td><td colspan="2">Reduction</td></tr><tr><td>Low (n = 6987)</td><td>Medium (n = 5926)</td><td>High (n = 1271)</td><td>Low</td><td>Medium</td><td>High</td><td>Medium</td><td>High</td></tr><tr><td colspan="9">Hospitalisations per person</td></tr><tr><td>Diabetes</td><td>5 (1421)</td><td>1.1 (1892)</td><td>1 (772)</td><td>4.87-5.11</td><td>1.06-1.16</td><td>0.89-1.04</td><td>78%</td><td>80%</td></tr><tr><td>IHD</td><td>5.9 (612)</td><td>2.3 (626)</td><td>1.5 (340)</td><td>5.69-6.08</td><td>2.22-2.47</td><td>1.34-1.6</td><td>61%</td><td>75%</td></tr><tr><td>COPD</td><td>3.4 (572)</td><td>1.3 (657)</td><td>1 (322)</td><td>3.27-3.58</td><td>1.18-1.35</td><td>0.92-1.15</td><td>62%</td><td>71%</td></tr><tr><td>Renal Disease</td><td>7.7 (1143)</td><td>1.2 (1923)</td><td>1.1 (826)</td><td>7.54-7.87</td><td>1.16-1.26</td><td>1.06-1.2</td><td>84%</td><td>86%</td></tr><tr><td>Hypertension</td><td>4 (1433)</td><td>1.1 (1986)</td><td>0.9 (832)</td><td>3.92-4.13</td><td>1.07-1.16</td><td>0.88-1.01</td><td>73%</td><td>78%</td></tr><tr><td colspan="9">PAHs</td></tr><tr><td>Diabetes</td><td>2.7</td><td>0.6</td><td>0.5</td><td>2.6-2.78</td><td>0.6-0.67</td><td>0.48-0.59</td><td>76%</td><td>80%</td></tr><tr><td>IHD</td><td>4</td><td>1.5</td><td>0.9</td><td>3.8-4.12</td><td>1.43-1.63</td><td>0.84-1.05</td><td>63%</td><td>78%</td></tr><tr><td>COPD</td><td>2</td><td>0.8</td><td>0.8</td><td>1.93-2.17</td><td>0.76-0.9</td><td>0.66-0.86</td><td>60%</td><td>60%</td></tr><tr><td>Renal Disease</td><td>3.4</td><td>0.5</td><td>0.6</td><td>3.31-3.53</td><td>0.5-0.57</td><td>0.54-0.65</td><td>85%</td><td>82%</td></tr><tr><td>Hypertension</td><td>2.3</td><td>0.7</td><td>0.5</td><td>2.19-2.35</td><td>0.64-0.71</td><td>0.49-0.6</td><td>70%</td><td>78%</td></tr><tr><td colspan="9">Deaths (per 100)</td></tr><tr><td>Diabetes</td><td>3.23</td><td>0.99</td><td>0.80</td><td>2.92-3.53</td><td>0.85-1.14</td><td>0.59-1</td><td>69%</td><td>75%</td></tr><tr><td>IHD</td><td>4.71</td><td>1.76</td><td>1.61</td><td>4.16-5.26</td><td>1.42-2.09</td><td>1.17-2.04</td><td>63%</td><td>66%</td></tr><tr><td>COPD</td><td>5.08</td><td>1.96</td><td>2.04</td><td>4.48-5.68</td><td>1.62-2.31</td><td>1.54-2.54</td><td>61%</td><td>60%</td></tr><tr><td>Renal Disease</td><td>4.21</td><td>1.18</td><td>1.06</td><td>3.82-4.59</td><td>1.02-1.34</td><td>0.83-1.29</td><td>72%</td><td>75%</td></tr><tr><td>Hypertension</td><td>3.11</td><td>1.28</td><td>0.97</td><td>2.82-3.41</td><td>1.12-1.44</td><td>0.75-1.19</td><td>59%</td><td>69%</td></tr><tr><td colspan="9">YLLs</td></tr><tr><td>Diabetes</td><td>1.00</td><td>0.24</td><td>0.20</td><td>0.99-1.02</td><td>0.23-0.24</td><td>0.19-0.21</td><td>76%</td><td>80%</td></tr><tr><td>IHD</td><td>1.47</td><td>0.46</td><td>0.39</td><td>1.44-1.5</td><td>0.44-0.47</td><td>0.37-0.41</td><td>69%</td><td>73%</td></tr><tr><td>COPD</td><td>1.32</td><td>0.41</td><td>0.44</td><td>1.29-1.35</td><td>0.39-0.42</td><td>0.41-0.46</td><td>69%</td><td>67%</td></tr><tr><td>Renal Disease</td><td>1.30</td><td>0.28</td><td>0.25</td><td>1.28-1.32</td><td>0.27-0.28</td><td>0.24-0.27</td><td>78%</td><td>81%</td></tr><tr><td>Hypertension</td><td>0.89</td><td>0.30</td><td>0.23</td><td>0.87-0.9</td><td>0.29-0.31</td><td>0.22-0.24</td><td>66%</td><td>74%</td></tr></table> |
c3edf7f07e71984efd3e6945369cc62df4fcb3eb45a0bd0993941391cc2f0198.png | simple | <table><tr><td>Clinical features</td><td>FA</td><td>XP</td><td>CS</td><td>TTD</td></tr><tr><td>Cancer</td><td>+</td><td>+</td><td>-</td><td>-</td></tr><tr><td>Skin pigmentation</td><td>+</td><td>+</td><td>-</td><td>±</td></tr><tr><td>Developmental delay</td><td>+</td><td>-</td><td>+</td><td>+</td></tr><tr><td>Neurological defects</td><td>±</td><td>±</td><td>+</td><td>+</td></tr></table> |
ea82c1d04c5a58b870ab9002df51197ce488b73c5e16e0cbd7e259efb6f79531.png | simple | <table><tr><td>Operational Mode</td><td>bits/s</td><td>kbits/sol</td><td>Power(mW)</td><td>Energy/sol(mWh)</td></tr><tr><td>Nominal (1sps during 5 min each hour)</td><td>112</td><td>806.4</td><td>0.25</td><td>0.5</td></tr><tr><td>In-flight calibration (1sps during 15 min each week)</td><td>112</td><td>14.4</td><td>500</td><td>17.8</td></tr><tr><td>Total</td><td>-</td><td>820.8</td><td>-</td><td>18.3</td></tr></table> |
13680045a5032785b0169e9636b906e5814e439a109b2c3ae66502f6221aa1a4.png | simple | <table><tr><td>Surgery Type (# of Patients) Ref.</td><td>Prognostic Value (Y/N/Insignificant)</td><td>Remarks</td></tr><tr><td>General/vascular surgery (143)39</td><td>Insignificant</td><td>Suggested conducting randomized control trial</td></tr><tr><td>Spine (268)40</td><td>Yes</td><td></td></tr><tr><td>General orthopedic (723)41</td><td>No</td><td>SAS did not predict 30-day major complications after general orthopedic surgery</td></tr><tr><td>Radical cystectomy (155)42</td><td>Yes</td><td></td></tr><tr><td>General surgery (2,125)43</td><td>Yes</td><td></td></tr><tr><td>Laparotomy (218)44</td><td>Yes</td><td></td></tr><tr><td>Non-cardiac surgeries (5,909)45</td><td>Yes</td><td></td></tr><tr><td>General and vascular surgeries (224)46</td><td>Yes</td><td></td></tr><tr><td>General, vascular, and orthopedic surgeries (223)47</td><td>Yes</td><td>SAS uncorrelated with orthopedic patients who had major events</td></tr><tr><td>Renal mass excision (886)48</td><td>Yes</td><td></td></tr><tr><td>High-risk intra-abdominal surgeries (355)49</td><td>Yes</td><td>SAS was significantly predictive but weakly discriminative for adverse events</td></tr></table> |
3653099e8b384fb9e2509599c2ea32ba36907ad39ecf532b7858b179efe13217.png | complex | <table><tr><td></td><td colspan="4">No. (%) of participants from</td></tr><tr><td></td><td>Eastern Croatia</td><td>Central Croatia</td><td>Southern Croatia</td><td>Croatia</td></tr><tr><td>pH≥7.3</td><td>75 (64.1)</td><td>144 (58.3)</td><td>167 (68.7)</td><td>386 (63.6)</td></tr><tr><td>pH<7.3</td><td>42 (35.9)</td><td>103 (41.7)</td><td>76 (31.3)</td><td>221 (36.4)</td></tr><tr><td>All</td><td>117 (19.3)</td><td>247 (40.7)</td><td>243 (40.0)</td><td>607 (100.0)</td></tr></table> |
0c4169dbb9ba10359efbed947e1412672f459abbbe61e509da474191fe9816dc.png | simple | <table><tr><td>Asset index items</td><td>Scoring factors</td><td>% of distribution in the sample</td><td>Most poor (%)</td><td>Least poor (%)</td></tr><tr><td>Refrigerator</td><td>0.382</td><td>48.4</td><td>0</td><td>100</td></tr><tr><td>Radio</td><td>0.231</td><td>65.8</td><td>41.1</td><td>91</td></tr><tr><td>Television</td><td>0.368</td><td>47.5</td><td>0</td><td>40</td></tr><tr><td>Stove</td><td>0.357</td><td>59.2</td><td>0</td><td>98</td></tr><tr><td>Phone</td><td>0.329</td><td>43.7</td><td>0</td><td>40</td></tr><tr><td>Car</td><td>0.161</td><td>7.3</td><td>0</td><td>21</td></tr><tr><td>Drinking water(Piped inside the house)</td><td>0.379</td><td>45.4</td><td>0</td><td>55</td></tr><tr><td>Type of toilet( Flush toilet)</td><td>0.358</td><td>48.2</td><td>0</td><td>41</td></tr><tr><td>Cooking fuel(Using electricity for cooking)</td><td>0.36</td><td>35.4</td><td>0</td><td>43</td></tr></table> |
30c9a388cfa6785fab079fb8d2fbff68b4de43aad1efbf47b5f1ae94394eb70b.png | simple | <table><tr><td>Molecular function term</td><td>% Coverage</td><td>p-value</td><td>FDR (%)</td></tr><tr><td>catalytic activity</td><td>43</td><td>1.32E-04</td><td>0.22</td></tr><tr><td>nucleotide binding</td><td>14</td><td>1.27E-05</td><td>0.02</td></tr><tr><td>purine nucleotide binding</td><td>13</td><td>4.74E-05</td><td>0.08</td></tr><tr><td>purine ribonucleotide binding</td><td>12</td><td>1.49E-05</td><td>0.02</td></tr><tr><td>ribonucleotide binding</td><td>12</td><td>1.49E-05</td><td>0.02</td></tr><tr><td>RNA binding</td><td>11</td><td>1.60E-09</td><td>2.71E-06</td></tr><tr><td>structural molecule activity</td><td>10</td><td>4.34E-12</td><td>7.36E-09</td></tr><tr><td>structural constituentof ribosome</td><td>9</td><td>4.38E-22</td><td>7.43E-19</td></tr><tr><td>GTP binding</td><td>3</td><td>7.43E-06</td><td>0.01</td></tr><tr><td>guanyl nucleotide binding</td><td>3</td><td>7.43E-06</td><td>0.01</td></tr><tr><td>guanyl ribonucleotide binding</td><td>3</td><td>7.43E-06</td><td>0.01</td></tr><tr><td>oxidoreductase activity, acting on CH-OH group of donors</td><td>3</td><td>4.66E-05</td><td>0.08</td></tr><tr><td>translation regulator activity</td><td>3</td><td>8.71E-07</td><td>1.48E-03</td></tr><tr><td>oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor</td><td>3</td><td>1.10E-04</td><td>0.19</td></tr><tr><td>translation factor activity, nucleic acid</td><td>3</td><td>2.14E-07</td><td>3.62E-04</td></tr><tr><td>GTPase activity</td><td>2</td><td>2.39E-03</td><td>3.98</td></tr><tr><td>rRNA binding</td><td>2</td><td>8.85E-11</td><td>1.50E-07</td></tr><tr><td>snoRNA binding</td><td>2</td><td>8.58E-09</td><td>1.45E-05</td></tr><tr><td>ligase activity, forming aminoacyl-tRNA and related compounds</td><td>2</td><td>1.33E-06</td><td>2.25E-03</td></tr><tr><td>ligase activity, forming carbon- oxygen bonds</td><td>2</td><td>1.33E-06</td><td>2.25E-03</td></tr><tr><td>aminoacyl-tRNA ligase activity</td><td>2</td><td>1.33E-06</td><td>2.25E-03</td></tr><tr><td>RNA helicase activity</td><td>2</td><td>4.29E-05</td><td>0.07</td></tr><tr><td>ATP-dependent RNA Helicase activity</td><td>2</td><td>9.12E-07</td><td>1.54E-03</td></tr><tr><td>RNA-dependent ATPase activity</td><td>2</td><td>9.12E-07</td><td>1.54E-03</td></tr><tr><td>translation initiation factor activity</td><td>1</td><td>4.61E-04</td><td>0.78</td></tr></table> |
fd17cdd862ff927c3061c5db9b7763178c983eb07325437a76349f350f288227.png | complex | <table><tr><td></td><td>No. of pts.</td><td>Spearmen-Rho</td><td>p-value</td></tr><tr><td>Quality of life</td><td></td><td></td><td></td></tr><tr><td>Health status</td><td>111</td><td>0.882</td><td>0.000</td></tr><tr><td>ICIQ (1)</td><td>111</td><td>−0.211</td><td>0.027</td></tr><tr><td>IPSS (2)</td><td>104</td><td>−0.204</td><td>0.037</td></tr><tr><td>Urethral D30 (3)</td><td></td><td></td><td></td></tr><tr><td>Volume of prostate</td><td>162</td><td>−0.326</td><td>0.000</td></tr><tr><td>IPSS at survey</td><td></td><td></td><td></td></tr><tr><td>IPSS (preimplant)</td><td>103</td><td>0.287</td><td>0.003</td></tr><tr><td colspan="2">Seed dislocation/loss</td><td></td><td></td></tr><tr><td>V100 (4)</td><td>163</td><td>−0.262</td><td>0.001</td></tr><tr><td>D90 (5)</td><td>163</td><td>−0.190</td><td>0.015</td></tr></table> |
37296058f9af828815c7198d93413596b70c017dfb5db2dd0ad4c81701021b5d.png | complex | <table><tr><td rowspan="2"></td><td rowspan="2">INTAKE24 Geometric Mean</td><td rowspan="2">Interview Geometric Mean</td><td rowspan="2">Ratio of Geometric Mean</td><td colspan="2">Limits of Agreement</td></tr><tr><td>Lower</td><td>Upper</td></tr><tr><td>Energy (kJ)</td><td>6681.7</td><td>6823.9</td><td>0.97</td><td>0.52</td><td>1.82</td></tr><tr><td>Carbohydrate (g)</td><td>234.2</td><td>236.0</td><td>0.99</td><td>0.52</td><td>1.88</td></tr><tr><td>NSP (g) </td><td>9.1</td><td>9.6</td><td>0.94</td><td>0.45</td><td>1.98</td></tr><tr><td>Fat (g)</td><td>52.3</td><td>55.8</td><td>0.92</td><td>0.43</td><td>1.96</td></tr><tr><td>Fat (%)</td><td>29.5</td><td>31.0</td><td>0.95</td><td>0.63</td><td>1.42</td></tr><tr><td>Saturated Fat (g)</td><td>19.2</td><td>20.5</td><td>0.92</td><td>0.39</td><td>2.17</td></tr><tr><td>Protein (g)</td><td>52.4</td><td>52.4</td><td>0.99</td><td>0.47</td><td>2.11</td></tr><tr><td>NMES (g) </td><td>89.3</td><td>85.3</td><td>1.07</td><td>0.28</td><td>4.05</td></tr><tr><td>NMES (%) </td><td>22.4</td><td>20.8</td><td>1.10</td><td>0.32</td><td>3.75</td></tr><tr><td>Alcohol (g)</td><td>0.01</td><td>0.01</td><td>0.95</td><td>0.29</td><td>3.10</td></tr><tr><td>Vitamin C (mg)</td><td>104.3</td><td>96.7</td><td>1.09</td><td>0.44</td><td>2.71</td></tr><tr><td>Iron (mg)</td><td>8.1</td><td>8.3</td><td>0.98</td><td>0.45</td><td>2.11</td></tr><tr><td>Calcium (mg)</td><td>713.9</td><td>705.8</td><td>1.00</td><td>0.46</td><td>2.18</td></tr></table> |
effc7b1a24c145d13d64b7c2afed15bc2648daf2e8a0da9c43b1952bb44d0677.png | complex | <table><tr><td rowspan="2">Wheat in OSR (in 2000)</td><td rowspan="2">Infectivity of Soil (% roots)a</td><td colspan="2">Take-All in Spring</td><td colspan="2">Take-All in Summer</td><td rowspan="2">Take-All Index (0–100)</td><td rowspan="2">Grain Yield (t ha<sup>−1</sup>)</td></tr><tr><td>Total(% plants)</td><td>No. Roots(plant<sup>−1</sup>)</td><td>Total (% plants)</td><td>Mod. (% plants)b</td></tr><tr><td>None</td><td>−2.55 (0.1)</td><td>−1.56 (3.8)</td><td>0.07</td><td>−1.73 (2.5)</td><td>−2.44 (0.3)</td><td>1.0</td><td>8.20</td></tr><tr><td>Destroyed early</td><td>−2.78 (0.0)</td><td>−1.81 (2.1)</td><td>0.06</td><td>−1.75 (2.4)</td><td>−2.24 (0.6)</td><td>1.7</td><td>8.56</td></tr><tr><td>Destroyed late</td><td>−2.03 (1.2)</td><td>−1.61 (3.4)</td><td>0.06</td><td>−1.81 (2.1)</td><td>−2.45 (0.2)</td><td>0.7</td><td>8.31</td></tr><tr><td>Not destroyed</td><td>−1.92 (1.6)</td><td>−1.12 (9.1)</td><td>0.25</td><td>−1.37 (5.5)</td><td>−2.09 (1.0)</td><td>3.5</td><td>8.46</td></tr><tr><td>SED (21 d.f.)</td><td>0.274</td><td>0.231</td><td>0.068</td><td>0.263</td><td>0.148</td><td>1.36</td><td>0.286</td></tr></table> |
368750988376f353fcb7dff27d89427b39011ce0e7238af916804bb397854163.png | simple | <table><tr><td>Organism</td><td>Release version</td><td>Coverage depth</td><td>Genome size (Mbp)</td><td>Scaffolds numbers</td><td>EST Size (Mbp)</td><td>EST numbers</td></tr><tr><td>Aq</td><td>v1.0</td><td>~8X</td><td>143</td><td>3,579</td><td>42</td><td>63,542</td></tr><tr><td>Ta</td><td>v1.0</td><td>~8.1X</td><td>107</td><td>1,415</td><td>8</td><td>11,498</td></tr><tr><td>Nv</td><td>v1.0</td><td>~7.8X</td><td>356</td><td>10,804</td><td>133</td><td>163,314</td></tr><tr><td>Ct</td><td>v1.0</td><td>~7.9X</td><td>334</td><td>21,042</td><td>119</td><td>209,323</td></tr><tr><td>Lg</td><td>v1.0</td><td>~8.9X</td><td>360</td><td>4,475</td><td>203</td><td>252,091</td></tr><tr><td>Bf</td><td>v2.0</td><td>~8.1 X</td><td>522</td><td>398</td><td>234</td><td>334,502</td></tr></table> |
fe4a173d6b62fdc1db01f7d35b8e671e7dac9b0ee373a2334cfcbccd43f726ce.png | simple | <table><tr><td>System</td><td>Manifestation</td></tr><tr><td>Digestive system</td><td>Burning throat, nausea, vomiting, abdominal pain, abdominal distension</td></tr><tr><td>Nervous system</td><td>Dizziness, vertigo, dysarthria, dysphagia, blurred vision, diplopia, drooping eyelids, mydriasis, miosis, absence of pupillary light reflex, gait ataxia, fatigue, convulsion, numbness, restlessness, loss of consciousness</td></tr><tr><td>Respiratory system</td><td>Chest tightness, tachypnea, bradypnea, shortness of breath, irregular breathing, respiratory arrest, cyanosis</td></tr><tr><td>Circulatory system</td><td>Palpitation, bradycardia, tachycardia, cardiac arrest, decrease of blood pressure</td></tr></table> |
865951c8ffd2a24a4ad00a307111864ed56a0471afb76906390cb77f86055a0a.png | complex | <table><tr><td>Entry Plasmids<sup>a</sup></td><td colspan="2">Applications</td></tr><tr><td colspan="2">pL1R5-BGHpA-empty</td><td>1. The TALEN Entry plasmid pairs can be used for </td></tr><tr><td colspan="2">pL1R5-CAG-EGFP-T2A-TALEN-NN-BGHpA</td><td> TALEN functional tests.</td></tr><tr><td colspan="2">pL1R5-CAG-EGFP-T2A-TALEN-NI-BGHpA</td><td>2. The TALEN Entry plasmids contain EGFP or</td></tr><tr><td colspan="2">pL1R5-CAG-EGFP-T2A-TALEN-NG-BGHpA</td><td>mCherry reporters, which can be used for</td></tr><tr><td colspan="2">pL1R5-CAG-EGFP-T2A-TALEN-HD-BGHpA</td><td>monitoring transfection efficiency and cell sorting.</td></tr><tr><td colspan="2"></td><td>3. Through LR recombination, the TALEN pairs can</td></tr><tr><td colspan="2">pL5L2-empty</td><td>be transferred to pPB-DEST or pPB-Puro-DEST or</td></tr><tr><td colspan="2">pL5L2-EF1α-mCherry-T2A-TALEN-NN</td><td>other destination vectors.</td></tr><tr><td colspan="2">pL5L2-EF1α-mCherry-T2A-TALEN-NI</td><td>4. TALENs in pL1R5-BGHpA vectors together with</td></tr><tr><td colspan="2">pL5L2-EF1α-mCherry-T2A-TALEN-NG</td><td>pL5L2 empty vector can be recombined into</td></tr><tr><td colspan="2">pL5L2-EF1α-mCherry-T2A-TALEN-HD</td><td>pAd/PL-DEST to produce adenoviruses with CAG</td></tr><tr><td colspan="2"></td><td>EGFP. Alternatively the reverse insertion of</td></tr><tr><td colspan="2">pL5L2-CAG-mCherry-T2A-TALEN-NN</td><td>TALENs in pL5L2 vectors together with pL1R5 -</td></tr><tr><td colspan="2">pL5L2-CAG-mCherry-T2A-TALEN-NI</td><td>BGHpA empty vector can be recombined into</td></tr><tr><td colspan="2">pL5L2-CAG-mCherry-T2A-TALEN-NG</td><td>pAd/PL-DEST to produce adenoviruses with EF1α</td></tr><tr><td colspan="2">pL5L2-CAG-mCherry-T2A-TALEN-HD</td><td>mCherry or CAG-mCherry.</td></tr></table> |
47a41b043459c22d7f5f131dc93008d7c2225842cf8ecf8924864a5c2247ac2b.png | complex | <table><tr><td>Gene</td><td>Primers</td><td>Sequence</td></tr><tr><td rowspan="2"><i>PRP8</i></td><td>Forward</td><td>TCATGGCTGCGTCTGAAGTA</td></tr><tr><td>Reverse</td><td>GGCTCAAACCCTTCCGATAG</td></tr><tr><td rowspan="2"><i>MET18</i></td><td>Forward</td><td>TGCTGGAAGTTGTCGTTGC</td></tr><tr><td>Reverse</td><td>TCGTTTTTGGAGAGGTGGTC</td></tr><tr><td rowspan="2"><i>CTT1</i></td><td>Forward</td><td>GATTCCGTTCTACAAGCCAGAC</td></tr><tr><td>Reverse</td><td>GGAGTATGGACATCCCAAGTTTC</td></tr><tr><td rowspan="2"><i>CTA1</i></td><td>Forward</td><td>CCAACAGGACAGACCCATTC</td></tr><tr><td>Reverse</td><td>TTACCCAAAACGCGGTAGAG</td></tr></table> |
e006f5b82dc53de5708b99d445ff98e44016afc8f96a096dd109b610be9beb51.png | simple | <table><tr><td>Species</td><td># of Strains</td><td>Genome size (Mb)</td><td>GC content (%)</td></tr><tr><td>Fungi (Kingdom)</td><td></td><td></td><td></td></tr><tr><td> Ascomycota (Phylum)</td><td></td><td></td><td></td></tr><tr><td>Pezizomycotina (Subphylum)</td><td></td><td></td><td></td></tr><tr><td><i>Aspergillus fumigatus</i></td><td>2</td><td>29.3 ± 0.1</td><td>49.672 ± 0.178</td></tr><tr><td><i>Aspergillus niger</i></td><td>2</td><td>35.6 ± 2.3</td><td>50.365 ± 0.012</td></tr><tr><td><i>Coccidioides immitis</i></td><td>4</td><td>28.3 ± 0.7</td><td>46.529 ± 0.514</td></tr><tr><td><i>Coccidioides posadasii</i></td><td>11</td><td>27.2 ± 0.9</td><td>46.839 ± 0.537</td></tr><tr><td><i>Histoplasma capsulatum</i></td><td>5</td><td>36.2 ± 4.7</td><td>43.400 ± 1.859</td></tr><tr><td><i>Paracoccidioides brasiliensis</i></td><td>3</td><td>30.7 ± 2.0</td><td>43.868 ± 0.930</td></tr><tr><td><i>Fusarium graminearum</i><sup>a</sup></td><td>2</td><td>36.6</td><td>48.283</td></tr><tr><td>Saccharomycotina (Subphylum)</td><td></td><td></td><td></td></tr><tr><td><i>Candida albicans</i></td><td>2</td><td>14.4 ± 0.1</td><td>33.462 ± 0.010</td></tr><tr><td><i>Saccharomyces cerevisiae</i></td><td>3</td><td>11.9 ± 0.3</td><td>38.252 ± 0.090</td></tr><tr><td><i>Saccharomyces bayanus</i></td><td>2</td><td>11.7 ± 0.3</td><td>40.196 ± 0.011</td></tr><tr><td><i>Saccharomyces mikatae</i><sup>b</sup></td><td>2</td><td>11.1 ± 0.5</td><td>37.920 ± 0.315</td></tr><tr><td>Basidiomycota (Phylum)</td><td></td><td></td><td></td></tr><tr><td>Agricomycotina (Subphylum)</td><td></td><td></td><td></td></tr><tr><td><i>Cryptococcus neoformans</i></td><td>4</td><td>19.2 ± 0.2</td><td>48.251 ± 0.316</td></tr><tr><td>Ustilaginomycotina (Subphylum)</td><td></td><td></td><td></td></tr><tr><td><i>Ustilago maydis</i></td><td>2</td><td>19.7 ± 0.0</td><td>53.995 ± 0.045</td></tr><tr><td>Chytridiomycota (Phylum)</td><td></td><td></td><td></td></tr><tr><td><i>Batrachochytrium dendrobatidis</i></td><td>2</td><td>24.1 ± 0.3</td><td>39.261 ± 0.011</td></tr><tr><td>Chloroplastida (Kingdom)</td><td></td><td></td><td></td></tr><tr><td> Charophyta (Phylum)</td><td></td><td></td><td></td></tr><tr><td><i>Oryza sativa</i></td><td>2</td><td>399.2 ± 38.4</td><td>43.530 ± 0.046</td></tr><tr><td>Vertebrata (Phylum)</td><td></td><td></td><td></td></tr><tr><td> Vertebrata (Phylum)</td><td></td><td></td><td></td></tr><tr><td><i>Homo sapiens</i></td><td>4</td><td>3,052.2 ± 409.3</td><td>40.878 ± 0.042</td></tr></table> |
4410a7f69337c6b43d291d33b27ba0ca8cf9add20b1e2eb1e62a33a116357573.png | simple | <table><tr><td>Complication</td><td>Evisceration Incidence/%</td><td>Enucleation Incidence/%</td><td><i>P</i> value (Fisher’s exact test)</td></tr><tr><td>No complication</td><td>30/71.4</td><td>16/61.5</td><td>0.43</td></tr><tr><td>Wound dehiscence</td><td>4/9.5</td><td>3/11.5</td><td>1.00</td></tr><tr><td>Implant exposure</td><td>2/4.8</td><td>1/3.8</td><td>1.00</td></tr><tr><td>Implant extrusion</td><td>1/2.4</td><td>2/7.7</td><td>0.55</td></tr><tr><td>Implant migration</td><td>0/0</td><td>1/3.8</td><td>0.38</td></tr><tr><td>Infection</td><td>2/4.8</td><td>1/3.8</td><td>1.00</td></tr><tr><td>Deep superior sulcus</td><td>3/7.1</td><td>2/7.7</td><td>1.00</td></tr><tr><td>Total</td><td>42/100</td><td>26/100</td><td></td></tr></table> |
6ba7f519becd9d32ab88de11e4961610c2474ce4ed6b4d91ae42948abb082534.png | complex | <table><tr><td colspan="2"></td><td colspan="6">Female</td></tr><tr><td rowspan="2"></td><td>Genotype</td><td colspan="3">wt/wt</td><td colspan="3">KO/KO</td></tr><tr><td>Treatment</td><td>Vehicle</td><td>AngII</td><td>Δ</td><td>Vehicle</td><td>AngII</td><td>Δ</td></tr><tr><td rowspan="5">Aorta</td><td>HR (bpm)</td><td>515.6 ± 8.0</td><td>512.3 ± 7.1</td><td>− 3.3</td><td>504.4 ± 6.8</td><td>503.6 ± 3.6</td><td>− 0.8</td></tr><tr><td>SP (mmHg)</td><td>109.3 ± 3.3</td><td><i>135.5 ± 4.1</i>*</td><td>26.2</td><td>119.7 ± 6.3</td><td>130.9 ± 3.7</td><td>11.2</td></tr><tr><td>DP (mmHg)</td><td>78.1 ± 2.3</td><td>83.7 ± 2.5</td><td>5.6</td><td>83.1 ± 2.8</td><td>86.8 ± 2.4</td><td>3.7</td></tr><tr><td>MAP (mmHg)</td><td>88.5 ± 2.6</td><td><i>101 ± 2.8</i>*</td><td>12.5</td><td>95.3 ± 3.9</td><td>101.5 ± 2.7</td><td>6.2</td></tr><tr><td>PP (mmHg)</td><td>31.2 ± 1.2</td><td><i>51.8 ± 3.0</i>*</td><td>20.6</td><td>36.6 ± 3.6</td><td>44.0 ± 2.2</td><td>7.4</td></tr><tr><td rowspan="5">LV</td><td>HR (bpm)</td><td>500.9 ± 8.2</td><td>500.4 ± 2.2</td><td>− 0.5</td><td>514.0 ± 9.6</td><td>508.9 ± 4.8</td><td>− 5.1</td></tr><tr><td>SP (mmHg)</td><td>106.5 ± 3.1</td><td><i>128.8 ± 1.5</i>*</td><td>22.3</td><td>112.9 ± 4.7</td><td><i>126.4 ± 2.6</i>*</td><td>13.5</td></tr><tr><td>EDP (mmHg)</td><td>6.4 ± 0.5</td><td>7.0 ± 1.1</td><td>0.6</td><td>5.3 ± 0.3</td><td><i>8.7 ± 1.1</i>*</td><td>3.4</td></tr><tr><td>dP/dT max (mmHg/s)</td><td>9799 ± 860.0</td><td>10,998 ± 426.2</td><td>1199</td><td>11,343 ± 745</td><td>12,455 ± 383.9</td><td>1112</td></tr><tr><td>dP/dT min (mmHg/s)</td><td>− 9019 ± 853.7</td><td>− 9253 ± 584.0</td><td>− 234</td><td>− 9262 ± 470.2</td><td>− 9718 ± 330.8</td><td>− 456</td></tr><tr><td rowspan="6">Morphometry</td><td>Body weight (g)</td><td>21.2 ± 0.3</td><td>22.3 ± 0.3</td><td>1.1</td><td>23.3 ± 0.5</td><td>22.3 ± 0.3</td><td>−1.0</td></tr><tr><td>Tibia length (mm)</td><td>16.1 ± 0.1</td><td>16.1 ± 0.1</td><td>0</td><td>16.4 ± 0.1</td><td>16.4 ± 0.1</td><td>0</td></tr><tr><td>HW:TL (mg/mm)</td><td>6.5 ± 0.1</td><td><i>8.1 ± 0.2</i>*</td><td>1.6</td><td>6.8 ± 0.1</td><td><i>8.2 ± 0.2</i>*</td><td>1.4</td></tr><tr><td>LVW:TL (mg/mm)</td><td>4.6 ± 0.1</td><td><i>6.0 ± 0.2</i>*</td><td>1.4</td><td>4.9 ± 0.1</td><td><i>6.2 ± 0.1</i>*</td><td>1.3</td></tr><tr><td>RVW:TL (mg/mm)</td><td>1.4 ± 0.0</td><td>1.4 ± 0.0</td><td>0</td><td>1.4 ± 0.0</td><td>1.4 ± 0.0</td><td>0</td></tr><tr><td>Lung:TL (mg/mm)</td><td>9.9 ± 0.4</td><td>9.5 ± 0.3</td><td>− 0.4</td><td>9.3 ± 0.5</td><td>9.7 ± 0.4</td><td>0.4</td></tr></table> |
842a1a29fcbd8f1ebae85412e9f65be315a48f4771cdb7313ddc58a42eee5719.png | simple | <table><tr><td>Epigenetic Process</td><td>Target</td><td>Function</td></tr><tr><td>DNA Methylation</td><td>DNA in cell or viral epigenome</td><td>Typically silence genes</td></tr><tr><td>Nucleosome Location</td><td>Cellular and Viral Chromatin</td><td>Nucleosome position controls access to DNA sequences</td></tr><tr><td>Histone Modification</td><td>Cellular and Viral Chromatin</td><td>Histone acetylation and methylation on H3K4/H3K36 association with activation of transcription, methylation on H3K9 and H3K27 is associated with repression, methylation of H4K20 could result in either activation or repression</td></tr><tr><td>Histone Variants</td><td>Cellular and Viral Chromatin</td><td>Not yet well understood for viruses</td></tr><tr><td>miRNA</td><td>Cellular and Viral Chromatin</td><td>Modify gene expression at the level of translation</td></tr></table> |
921526c2d697de2ea9fb0498cb835e2b73583cfcc390538a38962556d02cdc54.png | complex | <table><tr><td>Chromosomes</td><td colspan="4">% Aneuploidy (loss, gain)</td></tr><tr><td></td><td>Healthy brain</td><td>AT</td><td>AD</td><td>Schizo</td></tr><tr><td>1</td><td>0.5 (0.3, 0.2)</td><td>2.8 (1.7, 1.1)</td><td>0.7 (0.3, 0.4)</td><td>1.8 (0.9, 0.9)</td></tr><tr><td>7</td><td>0.7 (0.3, 0.4)</td><td>1.5 (0.6, 0.8)</td><td>NA</td><td>NA</td></tr><tr><td>8</td><td>1.0 (0.3, 0.7)</td><td>2.8 (0.8, 2.0)</td><td>NA</td><td>NA</td></tr><tr><td>9</td><td>1.2 (0.5, 0.7)</td><td>1.3 (0.6, 0.7)</td><td>NA</td><td>NA</td></tr><tr><td>11</td><td>0.8 (0.4, 0.3)</td><td>3.1 (1.5, 1.5)</td><td>1.1 (0.7, 0.4)</td><td>NA</td></tr><tr><td>16</td><td>0.7 (0.1, 0.6)</td><td>2.8 (0.4, 2.5)</td><td>NA</td><td>NA</td></tr><tr><td>17</td><td>2.2 (0.4, 1.8)</td><td>2.4 (1.2, 1.2)</td><td>7.7 (0.5, 7.2)</td><td>NA</td></tr><tr><td>18</td><td>0.9 (0.5, 0.4)</td><td>2.5 (1.2, 1.2)</td><td>1.0 (0.5, 0.4)</td><td>0.5 (NR, 0.5)</td></tr><tr><td>21</td><td>2.5 (1.3, 1.3)</td><td>NA</td><td>10.7 (4.1, 6.6)</td><td>NA</td></tr><tr><td>X</td><td>0.7 (0.3, 0.4)</td><td>1.8 (0.3, 1.5)</td><td>1.9 (0.7, 1.2)</td><td>1.2 (NR, 1.2)</td></tr><tr><td>Y</td><td>0.2 (0.1, 0.1)</td><td>0.6 (0.0, 0.6)</td><td>NA</td><td>NA</td></tr></table> |
1744ba411261a53e6264f908ba6e1d79607420c156196bb4239c7a85eb1500a7.png | simple | <table><tr><td>Different techniques</td><td>NESP for single pulse</td><td>Ave. NESP for orthogonal pulses</td></tr><tr><td>Seventh derivative Gaussian pulse [35]</td><td>46%</td><td>-</td></tr><tr><td>Hermite Gaussian Functions [20]</td><td>65%</td><td>65%</td></tr><tr><td>PM algorithm [10]</td><td>72.41%</td><td>-</td></tr><tr><td>SOCP based FIR filter [14]</td><td>79%</td><td>77.5%</td></tr><tr><td>SOCP based FIR filter [13]</td><td>92.16%</td><td>59.26%</td></tr><tr><td>Proposed UWB pulse</td><td>98.7%</td><td>98.7%</td></tr></table> |
02ddf452dfb66d38d1258561b3121889f875d567815fb0c80fa9cae7e443475f.png | complex | <table><tr><td> </td><td colspan="3">KPs</td><td colspan="3">Aqueous cells</td><td colspan="3">Aqueous flare</td><td colspan="3">Vitreous cells</td></tr><tr><td>Patient number</td><td>0</td><td>1</td><td>3</td><td>0</td><td>1</td><td>3</td><td>0</td><td>1</td><td>3</td><td>0</td><td>1</td><td>3</td></tr><tr><td>1</td><td>+++</td><td>++</td><td>±</td><td>+++</td><td>++</td><td>+</td><td>+++</td><td>++</td><td>+</td><td>++</td><td>+</td><td>±</td></tr><tr><td>2</td><td>+++</td><td>+</td><td>−</td><td>++</td><td>+</td><td>−</td><td>+++</td><td>+</td><td>+</td><td>−</td><td>−</td><td>−</td></tr><tr><td>3</td><td>+++</td><td>++</td><td>−</td><td>++</td><td>+</td><td>−</td><td>++</td><td>+</td><td>−</td><td>−</td><td>−</td><td>−</td></tr><tr><td>4</td><td>++</td><td>+</td><td>−</td><td>++</td><td>+</td><td>−</td><td>++</td><td>+</td><td>−</td><td>+</td><td>±</td><td>−</td></tr><tr><td>5</td><td>+++</td><td>++</td><td>±</td><td>+++</td><td>+</td><td>±</td><td>+++</td><td>++</td><td>±</td><td>++</td><td>+</td><td>+</td></tr><tr><td>6</td><td>++</td><td>+</td><td>+</td><td>++</td><td>+</td><td>−</td><td>++</td><td>+</td><td>−</td><td>−</td><td>−</td><td>−</td></tr></table> |
17bdc360e88ce805de439c15bab48b5fb465698327ae9f1268302a553627d864.png | simple | <table><tr><td>Placing State</td><td>Other Experiment Settings</td></tr><tr><td>Static</td><td>Running the whole ARS</td></tr><tr><td>Static</td><td>Only running Sensors</td></tr><tr><td>Static</td><td>Running the ARS without activity recognition and result processing</td></tr><tr><td>Static</td><td>Running the ARS without result processing</td></tr><tr><td>Static</td><td>The phone on standby</td></tr><tr><td>Shaker</td><td>Running the whole ARS</td></tr><tr><td>Shaker</td><td>Only running Sensors</td></tr><tr><td>Shaker</td><td>Running the ARS without activity recognition and result processing</td></tr><tr><td>Shaker</td><td>Running the ARS without result processing</td></tr><tr><td>Shaker</td><td>The phone on standby</td></tr></table> |
b7e87d60cb541ef7ae75641dbb3b0d092af0c4c98f535ab474889aba20070123.png | complex | <table><tr><td rowspan="2"></td><td>Lower UTI</td><td>Control</td><td rowspan="2">P value</td></tr><tr><td>(n = 13)</td><td>(n = 24)</td></tr><tr><td rowspan="2">Leucocyte count (G/l)</td><td>8.6 ± 3.3</td><td>6.43 ± 2.1</td><td rowspan="2">NS</td></tr><tr><td>[7.4 (3.4)]</td><td>[5.6 (3.3)]</td></tr><tr><td rowspan="2">hsCRP (mg/L)</td><td>2.9 ± 1.7</td><td>3.5 ± 2.3</td><td rowspan="2">NS</td></tr><tr><td>[2.28 (2.81)]</td><td>[3.3 (2.5)]</td></tr><tr><td rowspan="2">PCT (ng/ml)</td><td>0.05 ± 0</td><td>0.06 ± 0.02</td><td rowspan="2">NS</td></tr><tr><td>[0.05 (0)]</td><td>[0.05 (0)]</td></tr><tr><td rowspan="2">IL −6 (pg/ml)</td><td>22.5 ± 1.6</td><td>3.1 ± 1.6</td><td rowspan="2"><0.001</td></tr><tr><td>[5.8 (41.9)]</td><td>[2.8 (2)]</td></tr><tr><td rowspan="2">CPP (pg/ml)</td><td>2253 ± 1323</td><td>224 ± 109</td><td rowspan="2"><0.001</td></tr><tr><td>[1757 (1403)]</td><td>[209 (141)]</td></tr></table> |
86e6d91cbfded9d9436718e97ce3eeddc6a11eeee86728808be7f011a8343d69.png | complex | <table><tr><td>Method</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>6</td><td>7</td><td>8</td><td>9</td></tr><tr><td colspan="10">A.RANKING ORDER UNDER ALL STRESS(BETTER-GOOD-AVERAGE)</td></tr><tr><td> geNorm</td><td>MAP/UBC</td><td></td><td>FHP</td><td>EF 1-α</td><td>CGS1</td><td>PPK</td><td>ATPase</td><td>eif4A</td><td>DPE2</td></tr><tr><td> NormFinder</td><td>UBC</td><td>MAP</td><td>EF 1-α</td><td>FHP</td><td>CGS1</td><td>PPK</td><td>eif4A</td><td>ATPase</td><td>DPE2</td></tr><tr><td> BestKeeper</td><td>MAP</td><td>UBC</td><td>FHP</td><td>PPK</td><td>CGS1</td><td>EF 1-α</td><td>ATPase</td><td>eif4A</td><td>DPE2</td></tr><tr><td> Δct method</td><td>UBC</td><td>MAP</td><td>FHP</td><td>EF 1-α</td><td>CGS1</td><td>ATPase</td><td>eif4A</td><td>PPK</td><td>DPE2</td></tr><tr><td> Comprehensive ranking</td><td>UBC</td><td>MAP</td><td>FHP</td><td>EF 1-α</td><td>CGS1</td><td>PPK</td><td>ATPase</td><td>eif4A</td><td>DPE2</td></tr><tr><td colspan="10">B.RANKING ORDER UNDER DEHYDRATION STRESS (BETTER-GOOD-AVERAGE)</td></tr><tr><td> geNorm</td><td>CGS1/FHP</td><td></td><td>PPK</td><td>UBC</td><td>MAP</td><td>EF 1-α</td><td>eif4A</td><td>DPE2</td><td>ATPase</td></tr><tr><td> NormFinder</td><td>UBC</td><td>CGS1</td><td>FHP</td><td>MAP</td><td>EF 1-α</td><td>PPK</td><td>eif4A</td><td>DPE2</td><td>ATPase</td></tr><tr><td> BestKeeper</td><td>CGS1</td><td>FHP</td><td>PPK</td><td>UBC</td><td>MAP</td><td>EF 1-α</td><td>DPE2</td><td>ATPase</td><td>eif4A</td></tr><tr><td> Δct method</td><td>UBC</td><td>CGS1</td><td>FHP</td><td>MAP</td><td>PPK</td><td>EF 1-α</td><td>eif4A</td><td>ATPase</td><td>DPE2</td></tr><tr><td> Comprehensive ranking</td><td>CGS1</td><td>UBC</td><td>FHP</td><td>PPK</td><td>MAP</td><td>EF 1-α</td><td>eif4A</td><td>DPE2</td><td>ATPase</td></tr><tr><td colspan="10">C.RANKING ORDER UNDER TEMPERATURE STRESS (BETTER-GOOD-AVERAGE)</td></tr><tr><td> geNorm</td><td>MAP/ATPase</td><td></td><td>EF 1-α</td><td>UBC</td><td>CGS1</td><td>FHP</td><td>PPK</td><td>DPE2</td><td>eif4A</td></tr><tr><td> NormFinder</td><td>UBC</td><td>MAP</td><td>CGS1</td><td>EF 1-α</td><td>ATPase</td><td>FHP</td><td>DPE2</td><td>PPK</td><td>eif4A</td></tr><tr><td> BestKeeper</td><td>MAP</td><td>ATPase</td><td>UBC</td><td>CGS1</td><td>PPK</td><td>EF 1-α</td><td>FHP</td><td>DPE2</td><td>eif4A</td></tr><tr><td> Δct method</td><td>UBC</td><td>MAP</td><td>ATPase</td><td>EF 1-α</td><td>CGS1</td><td>FHP</td><td>DPE2</td><td>PPK</td><td>eif4A</td></tr><tr><td> Comprehensive ranking</td><td>MAP</td><td>UBC</td><td>CGS1</td><td>ATPase</td><td>EF 1-α</td><td>FHP</td><td>PPK</td><td>DPE2</td><td>eif4A</td></tr></table> |
fac201ab137d74e2e66bb4ca21c63894f37dbe3b6919c4e32f2755b8719ce516.png | simple | <table><tr><td>System</td><td>Effect</td><td>Manifestation</td></tr><tr><td><i>Renal</i></td><td>Renal vein compression, cortical arteriolar compression</td><td>Oliguria, rising creatinine</td></tr><tr><td><i>Pulmonary</i></td><td>Upward pressure on diaphragm, decreased compliance and functional residual capacity, increased air way resistance</td><td>Hypoxia, hypercarbia, elevated airway pressure, decreased tidal volume</td></tr><tr><td><i>Cardiovascular</i></td><td>Decreased venous return, increased afterload</td><td>Decreased cardiac output</td></tr><tr><td><i>Cerebral</i></td><td>Increased intrathoracic pressure with decreased cerebral venous outflow</td><td>Elevated Intra Cranial Pressure</td></tr><tr><td><i>Splanchnic</i></td><td>Decreased perfusion of liver and intestine</td><td>Metabolic acidosis, bowel ischemia</td></tr></table> |
fa3290320e813dc4178a8500f8f94a56429600a3c3510066285ce69a5a123e47.png | simple | <table><tr><td></td><td>Ever Delirium (n = 125)</td><td>Never Delirium (n = 135)</td><td>p-value</td></tr><tr><td>Characteristic</td><td></td><td></td><td></td></tr><tr><td> Mean age (± 1 SD; years)</td><td>56 (± 18)</td><td>49 (± 17)</td><td>0.002</td></tr><tr><td> Male</td><td>62 (50%)</td><td>67 (50%)</td><td>1.0</td></tr><tr><td> No. of Caucasians</td><td>99 (79%)</td><td>115 (85%)</td><td>0.25</td></tr><tr><td> APACHE II score, median (IQR)</td><td>15 (10–21)</td><td>11 (6–16)</td><td><0.001</td></tr><tr><td> Charlson co-morbidity index, median (IQR)</td><td>4 (2–7)</td><td>3 (1–6)</td><td>0.079</td></tr><tr><td>Diagnostic category for ICU admission (%)b</td><td></td><td></td><td></td></tr><tr><td> Pulmonary</td><td>29</td><td>40</td><td></td></tr><tr><td> Gastrointestinal</td><td>20</td><td>21</td><td></td></tr><tr><td> Metabolic</td><td>22</td><td>18</td><td></td></tr><tr><td> Cardiac</td><td>7</td><td>9</td><td></td></tr><tr><td> Hematology/oncology</td><td>5</td><td>4</td><td></td></tr><tr><td> Neurologic</td><td>5</td><td>3</td><td></td></tr><tr><td> Renal</td><td>9</td><td>2</td><td></td></tr><tr><td> Other</td><td>3</td><td>3</td><td></td></tr></table> |
725f720b63be604ffa8cf2e937c05e183ecf39af4db187d9d6aa571998b21e54.png | simple | <table><tr><td></td><td><i>Function-based screening</i></td><td><i>Sequence-based screening</i></td><td><i>SIGEX</i></td></tr><tr><td>Screening principle</td><td>• Detecting changes by enzymatic reactions (e.g. halo formation around the colonies)</td><td>• PCR or Southern hybridization based on the DNA sequence consensus</td><td>• Trapping the operon induced by a substrate and sorting using FACS</td></tr><tr><td>Advantages</td><td>• Secures a complete form of gene or gene cluster required for desired traits• Potentially obtains completely novel genes.</td><td>• Overcomes the limitations of the heterologous expression</td><td>• Fast and economical• Any substrates that can be introduced into cytoplasm can be used in its native forms.</td></tr><tr><td>Disadvantages</td><td>• Must satisfy the expression conditions (transcription, translation, folding, secretion) in heterologous hosts</td><td>• Requires a database and analyses of the DNA sequence consensus.• Does not guarantee the acquisition of complete forms of genes or gene clusters.</td><td>• Sensitive to the orientation of the genes with desired traits• Cannot use substrates that do not migrate to cytoplasm• Sensitive to the initial FACS setting</td></tr><tr><td>Examples</td><td>antibiotics [9, 19-22], genes involved antibiotic resistance [9, 23, 24], agarases [15], amidases [13], amylases [15, 21, 25, 26], esterase/lipases [8, 15, 21, 27, 28], xylanases [29], 4-hydoxybutyrate dehydrogenase [30] alcohol oxidoreductases [14], pectate lyases [31]</td><td>amylases [26], polyketide synthases [32, 33]</td><td>Benzoate-degratative or catechol degradative operon, P450 enzyme [16]</td></tr></table> |
7b3b138288508e9dbc62b2cae0675b7a2e0e13fd0184d78fff5b40d57d10bac1.png | simple | <table><tr><td>Instrument</td><td>FAST Year 1</td><td>GDS Year 1</td><td>CDR-GS Year 1</td></tr><tr><td>AQ Year 1</td><td>0.84</td><td>0.78</td><td>0.74</td></tr><tr><td>FAQ Year 1</td><td>0.83</td><td>0.77</td><td>0.75</td></tr><tr><td>MMSE Year 1</td><td>-0.59</td><td>-0.64</td><td>-0.65</td></tr></table> |
cc5f0a891f5f8665bbf3289facddce86214205330b1e7e2b1db30f3ba356ae47.png | complex | <table><tr><td>Group</td><td>AGEs</td><td><i>p</i> Value</td><td>sRAGE</td><td><i>p</i> Value</td></tr><tr><td rowspan="2">Control group</td><td>16.89 ± 2.98</td><td>0.001</td><td>3.01 ± 1.53</td><td>0.0001</td></tr><tr><td>16.82 (11.1)</td><td></td><td>3 (3.8)</td><td></td></tr><tr><td>All Hemodialysis groups</td><td>18.92 ± 4.1517.9 (20.2)</td><td></td><td>8.23 ± 2.349.3 (9.6)</td><td></td></tr><tr><td rowspan="2">Diabetic HD</td><td>19.3 ± 4.69</td><td>0.001 *</td><td>8.97 ± 1.53</td><td>0.0001 *<sup>,</sup>#</td></tr><tr><td>18.5 (18)</td><td></td><td>9.6 (6.52)</td><td></td></tr><tr><td>Non-diabetic HD</td><td>18.75 ± 3.8917.8 (17.1)</td><td></td><td>7.89 ± 2.579.23 (9.6)</td><td></td></tr><tr><td>Control</td><td>16.89 ± 2.9916.82 (11.1)</td><td></td><td>3.01 ± 1.533 (3.8)</td><td></td></tr><tr><td rowspan="2">CVD</td><td>19.49 ± 4.34</td><td>0.24</td><td>9.03 ± 1.54</td><td>0.003</td></tr><tr><td>17.9 (18)</td><td></td><td>9.68 (6.43)</td><td></td></tr><tr><td>Non-CVD</td><td>18.6 ± 4.0317.9 (17.9)</td><td></td><td>7.77 ± 2.598.3 (9.6)</td><td></td></tr><tr><td>Hemodialysis sub-groups</td><td></td><td></td><td></td><td></td></tr><tr><td rowspan="2">DM<sup>+</sup>CVD<sup>+</sup> (1)</td><td>18.55 ± 5.23</td><td>0.011 ′′</td><td>8.97 ± 1.85</td><td>0.015 ′′</td></tr><tr><td>17.24 (18)</td><td></td><td>9.77 (6.4)</td><td></td></tr><tr><td>DM<sup>+</sup>CVD<sup>−</sup> (2)</td><td>20.09 ± 4.0321.03 (13.9)</td><td></td><td>8.97 ± 1.159.1 (2.77)</td><td></td></tr><tr><td>DM<sup>−</sup>CVD<sup>+</sup> (3)</td><td>20.25 ± 3.3819.6 (9.6)</td><td></td><td>9.09 ± 1.279.68 (3.83)</td><td></td></tr><tr><td>DM<sup>−</sup>CVD<sup>−</sup> (4)</td><td>18.13 ± 3.9516.98 (17.1)</td><td></td><td>7.39 ± 2.818.3 (9.6)</td><td></td></tr></table> |
4ba434bd3142dc1d62ae8361c775eae39fb898edc583d43c99379abf56f98adc.png | simple | <table><tr><td></td><td>odds ratio</td><td>95% CI</td><td><i>p</i>-value</td></tr><tr><td>Age, years (mean ± SD)</td><td>1.01</td><td>0.88–1.15</td><td>0.920</td></tr><tr><td>Education, years (mean ± SD)</td><td>1.02</td><td>0.88–1.21</td><td>0.778</td></tr><tr><td>Gender, female (%)</td><td>3.33</td><td>0.68–18.62</td><td>0.146</td></tr><tr><td>1st CDR-SB</td><td>0.90</td><td>0.63–1.28</td><td>0.573</td></tr><tr><td>1st MMSE</td><td>1.00</td><td>0.82–1.22</td><td>0.962</td></tr><tr><td>Cilostazol use</td><td>0.51</td><td>0.12–1.99</td><td>0.331</td></tr><tr><td>ApoE ε4(+),n (%)</td><td>0.39</td><td>0.07–1.92</td><td>0.248</td></tr></table> |
40b5d48412db4e4f8c7d12469477744ef1dc1297f5e7df4855230699d560c8ba.png | complex | <table><tr><td rowspan="3">Items</td><td colspan="3">single</td><td colspan="3">multiple</td></tr><tr><td>OR</td><td>95% CI</td><td><i>P</i></td><td>OR</td><td>95% CI</td><td><i>P</i></td></tr><tr><td>Sing songs with your child</td><td>1.82<sup>a</sup></td><td>1.10–3.01</td><td>0.0204</td><td>1.71<sup>a</sup></td><td>1.01–2.89</td><td>0.0475</td></tr><tr><td>Gender</td><td>2.74<sup>a</sup></td><td>1.10–6.82</td><td>0.0303</td><td>2.73<sup>a</sup></td><td>1.04–7.18</td><td>0.0416</td></tr><tr><td>Siblings</td><td>1.47</td><td>0.62–3.47</td><td>0.3799</td><td>1.70</td><td>0.68–4.22</td><td>0.2536</td></tr><tr><td>Family type</td><td>0.98</td><td>0.27–3.49</td><td>0.9722</td><td>0.89</td><td>0.22–3.70</td><td>0.8735</td></tr><tr><td>Mother’s age</td><td>0.49</td><td>0.21–1.17</td><td>0.1067</td><td>0.60</td><td>0.20–1.81</td><td>0.3631</td></tr><tr><td>Mother’s education</td><td>0.86</td><td>0.59–1.24</td><td>0.4141</td><td>0.85</td><td>0.56–1.29</td><td>0.4560</td></tr><tr><td>Mother’s occupation</td><td>0.77</td><td>0.33–1.76</td><td>0.5276</td><td>0.75</td><td>0.31–1.84</td><td>0.5340</td></tr><tr><td>Father’s age</td><td>0.62</td><td>0.32–1.19</td><td>0.1490</td><td>0.68</td><td>0.27–1.71</td><td>0.4093</td></tr><tr><td>Father’s education</td><td>1.05</td><td>0.79–1.39</td><td>0.7451</td><td>0.97</td><td>0.68–1.38</td><td>0.8496</td></tr><tr><td>Family’s economic status</td><td>1.38</td><td>0.88–2.15</td><td>0.1600</td><td>1.50</td><td>0.99–2.52</td><td>0.1239</td></tr><tr><td>H-L test (<i>P</i>)</td><td colspan="3">—</td><td colspan="3">0.3878</td></tr></table> |
986b9332db46d402c9e92493a900083f9721c7c62854046098086884b9452d43.png | simple | <table><tr><td>Pathology</td><td>Young</td><td>AdV</td><td>1 mo post DSB</td><td>2 mo post DSB</td><td>Old</td></tr><tr><td>Karyomegaly</td><td>1.62±0.38</td><td>2.27±0.14</td><td>3.00±0*</td><td>2.25±0.25</td><td>4.00±0**</td></tr><tr><td>Intranuclear inclusions</td><td>0±0</td><td>0.09±0.10</td><td>0.38±0.13<sup>#</sup></td><td>0.38±0.13<sup>#</sup></td><td>3.00±0**</td></tr><tr><td>Lobular infiltrates</td><td>0.38±0.24</td><td>0.81±0.26</td><td>1.63±0.13*</td><td>1.38±0.24</td><td>3.67±0.33**</td></tr><tr><td>Portal infiltrates</td><td>1.12±0.12</td><td>0.90±0.09</td><td>1.25±0.15*</td><td>1.25±0.25</td><td>2.33±0.66*</td></tr><tr><td>EMH</td><td>0±0</td><td>0±0</td><td>0.75±0.25*</td><td>0.25±0.25</td><td>2.33±0.66*</td></tr><tr><td>Lipofuscin</td><td>0.37±0.12</td><td>0.20±0.13</td><td>0.25±0.14</td><td>0±0</td><td>2.0±0.29*</td></tr></table> |
1988c9445646e6f45bf9c86abd5e9a520dda04cbc0c337f9618c6741559696bc.png | simple | <table><tr><td>Program</td><td>50</td><td>150</td><td>250</td></tr><tr><td>B-TBLASTN</td><td>0.458 ± 0.004</td><td>0.478 ± 0.002</td><td>0.484 ± 0.001</td></tr><tr><td>S-TBLASTN</td><td>0.454 ± 0.004</td><td>0.471 ± 0.002</td><td>0.478 ± 0.001</td></tr><tr><td>C-TBLASTN</td><td>0.455 ± 0.004</td><td>0.474 ± 0.002</td><td>0.481 ± 0.001</td></tr></table> |
f10037ed118c15afdfacb9c72cd17f5b192ae71a43ddddfae6366f253af9c157.png | simple | <table><tr><td>Classifier</td><td>Accuracy (%)</td><td>Recall rate (%)</td><td>F1 measure</td><td>Time (s)</td></tr><tr><td>EEG</td><td>94.2</td><td>92.8</td><td>93.7</td><td>0.01</td></tr><tr><td>Skeleton</td><td>93.8</td><td>93.4</td><td>93.8</td><td>0.01</td></tr><tr><td>Skeleton-EEG</td><td>94.7</td><td>94.6</td><td>94.2</td><td>0.01</td></tr><tr><td>Integrated</td><td>96.5</td><td>96.4</td><td>96.2</td><td>0.01</td></tr></table> |
d027f123a9098b0a9b638f69923509b060c01bab8b6d5c16de2ab300569342da.png | simple | <table><tr><td>Group</td><td>Cases, n</td><td>In-stent restenosis, n (%)</td><td>Angina, n (%)</td><td>Myocardial infarction, n (%)</td><td>Heart failure, n (%)</td><td>Revascularization (unchanged number), n (%)</td><td>All-cause mortality, n (%)</td><td>MACE events, n (%)</td><td>Medical costs, RMB</td></tr><tr><td>CR</td><td>1020</td><td>121 (11.9)</td><td>307 (30.1)</td><td>18 (1.7)</td><td>67 (6.5)</td><td>142 (13.9)</td><td>12 (1.2)</td><td>173 (17)</td><td>62,100</td></tr><tr><td>FR</td><td>856</td><td>111 (12.9)</td><td>246 (28.7)</td><td>19 (2.2)</td><td>84 (9.8)</td><td>111 (12.9)</td><td>15 (1.8)</td><td>248 (29)</td><td>83,200</td></tr><tr><td>PR</td><td>433</td><td>63 (14.6)</td><td>191 (44.1)</td><td>12 (2.8)</td><td>93 (21.4)</td><td>98 (22.8)</td><td>17 (3.9)</td><td>290 (67)</td><td>66,900</td></tr></table> |
b72d640426198afc796acd024515306e09523f87b7762329b8563026a0a9470d.png | complex | <table><tr><td></td><td colspan="4">Interval from calving</td></tr><tr><td></td><td>50-70</td><td>71-100</td><td>101-</td><td>Total</td></tr><tr><td>Parity</td><td></td><td></td><td></td><td></td></tr><tr><td> 0</td><td></td><td></td><td></td><td>27.3 (22)</td></tr><tr><td> 1</td><td>25.0 (8)</td><td>10.7 (28)</td><td>25.0 (8)</td><td>15.9 (44)</td></tr><tr><td> 2-5</td><td>18.2 (11)</td><td>16.9 (59)</td><td>25.0 (12)</td><td>18.3 (82)</td></tr><tr><td> 6-</td><td>25.0 (4)</td><td>40.0 (10)</td><td>50.0 (2)</td><td>37.5 (16)</td></tr><tr><td> Total</td><td>21.7 (23)</td><td>17.5 (97)</td><td>27.3 (22)</td><td></td></tr></table> |
5a356c8a391512de34f54f82da59d39b6d17b72513e2a45f49062aaa6aace6a2.png | simple | <table><tr><td>Probable</td></tr><tr><td>Probable CVID</td></tr><tr><td>Male or female patient who has a marked decrease of IgG (at least 2 SD below the mean for age) and a marked decrease in at least one of the isotypes IgM or IgA, and fulfils all of the following criteria:</td></tr><tr><td> ∙ Onset of immunodeficiency at >2 years of age</td></tr><tr><td> ∙ Absent isohemagglutinins and/or poor response to vaccines</td></tr><tr><td> ∙ Defined causes of hypogammaglobulinemia have been excluded</td></tr><tr><td>Possible CVID</td></tr><tr><td>Male or female patient who has a marked decrease (at least 2 SD below the mean for age) in at least one of the major isotypes (IgM, IgG, and IgA) and fulfils all of the following criteria:</td></tr><tr><td> 1. Onset of immunodeficiency at >2 years of age</td></tr><tr><td> 2. Absent isohemagglutinins and/or poor response to vaccines</td></tr><tr><td> 3. Defined causes of hypogammaglobulinemia have been excluded</td></tr></table> |
d8865e882302640e66a7ea6e30724756246dc4b7fe69bb912a1fe8b29c8bd0a1.png | simple | <table><tr><td>Affymetrix ID</td><td>FoldΔ</td><td>GenBank</td><td>Gene</td><td>Gene Description</td></tr><tr><td>1384944_at</td><td>43.3</td><td>BE116855</td><td>Bcl11b</td><td>B-cell leukemia/lymphoma 11B (predicted)</td></tr><tr><td>1370041_at</td><td>11.7</td><td>NM_053440</td><td>Stmn2</td><td>stathmin-like 2</td></tr><tr><td>1378776_at</td><td>6.8</td><td>BE097103</td><td>Pou6f1</td><td>POU domain, class 6, transcription factor 1</td></tr><tr><td>1368411_a_at</td><td>4.6</td><td>X74211</td><td>Mtap2</td><td>microtubule-associated protein 2</td></tr><tr><td>1391019_at</td><td>3.4</td><td>BF285698</td><td>Slitrk1</td><td>SLIT and NTRK-like family, member 1 (predicted)</td></tr><tr><td>1377308_a_at</td><td>3.4</td><td>BF398408</td><td></td><td>Neurotrophic tyrosine kinase, receptor, type 3</td></tr><tr><td>1368097_a_at</td><td>3.4</td><td>NM_053865</td><td>Rtn1</td><td>reticulon 1</td></tr><tr><td>1369765_at</td><td>3.3</td><td>NM_022384</td><td>Ascl1</td><td>achaete-scute complex homolog-like 1 (Drosophila)</td></tr><tr><td>1371618_s_at</td><td>3.3</td><td>AI229029</td><td>Tubb3</td><td>tubulin, beta 3</td></tr><tr><td>1370043_at</td><td>3.3</td><td>NM_031753</td><td>Alcam</td><td>activated leukocyte cell adhesion molecule</td></tr><tr><td>1372299_at</td><td>3.0</td><td>AI013919</td><td>Cdkn1c</td><td>cyclin-dependent kinase inhibitor 1C (P57)</td></tr><tr><td>1368261_at</td><td>2.7</td><td>NM_053817</td><td>Nrxn3</td><td>neurexin 3; hypothetical gene supported by NM_053817</td></tr><tr><td>1395357_at</td><td>2.7</td><td>BG672052</td><td>Map1b</td><td>microtubule-associated protein 1b</td></tr><tr><td>1390671_at</td><td>2.7</td><td>AI044666</td><td>Igf1r</td><td>Insulin-like growth factor 1 receptor</td></tr><tr><td>1373683_at</td><td>2.7</td><td>AI230396</td><td>Fyn</td><td>fyn proto-oncogene</td></tr><tr><td>1387200_at</td><td>2.6</td><td>NM_021770</td><td>Olig1</td><td>oligodendrocyte transcription factor 1</td></tr><tr><td>1392477_at</td><td>2.6</td><td>AI059914</td><td>Etv1</td><td>ets variant gene 1 (predicted)</td></tr><tr><td>1367918_at</td><td>2.5</td><td>NM_031066</td><td>Fez1</td><td>fasciculation and elongation protein zeta 1 (zygin I)</td></tr><tr><td>1387274_at</td><td>2.5</td><td>NM_012943</td><td>Dlx5</td><td>distal-less homeobox 5</td></tr><tr><td>1388015_at</td><td>2.4</td><td>U04998</td><td>Ptprz1</td><td>protein tyrosine phosphatase, receptor-type, Z polypept. 1</td></tr><tr><td>1379693_at</td><td>2.4</td><td>AI409154</td><td>Robo2</td><td>Roundabout 2 (Drosophila)</td></tr><tr><td>1395986_at</td><td>2.3</td><td>BF391439</td><td>Slit2</td><td>slit homolog 2 (Drosophila)</td></tr><tr><td>1388419_at</td><td>2.3</td><td>AW915005</td><td></td><td>CDK5 regulatory subunit associated protein 2</td></tr><tr><td>1369213_at</td><td>2.3</td><td>NM_017345</td><td></td><td>neural cell adhesion molecule L1</td></tr><tr><td>1379526_at</td><td>2.3</td><td>BG374506</td><td>Mbp</td><td>Myelin basic protein</td></tr><tr><td>1387424_at</td><td>2.2</td><td>NM_012884</td><td>Cntn2</td><td>contactin 2</td></tr><tr><td>1370124_at</td><td>2.2</td><td>NM_053968</td><td>Mt3</td><td>metallothionein 3</td></tr><tr><td>1368148_at</td><td>2.2</td><td>NM_012610</td><td>Ngfr</td><td>nerve growth factor receptor (TNFR superfamily, mem 16)</td></tr><tr><td>1381215_at</td><td>2.2</td><td>AA900967</td><td></td><td>PREDICTED: similar to Numbl protein [Rattus norvegicus]</td></tr><tr><td>1368472_at</td><td>2.1</td><td>NM_031320</td><td>Celsr3</td><td>cadherin EGF LAG seven-pass G-type receptor 3</td></tr><tr><td>1396150_at</td><td>2.1</td><td>AW917275</td><td>Cldn1</td><td>claudin 1</td></tr><tr><td>1374403_at</td><td>2.1</td><td>BF412072</td><td>Efnb1</td><td>ephrin B1</td></tr><tr><td>1382205_at</td><td>2.1</td><td>AW527509</td><td></td><td>Transcribed locus</td></tr><tr><td>1386948_at</td><td>2.0</td><td>NM_012987</td><td>Nes</td><td>Nestin</td></tr><tr><td>1368879_a_at</td><td>2.0</td><td>AF413212</td><td>Gnao</td><td>guanine nucleotide binding protein, alpha o</td></tr></table> |
4a455c9cb54bdee3f23cc5883c07f5fbc85b0b8b0412c98ef1ea399dd8d9b7d9.png | simple | <table><tr><td>G6PD Status</td><td>Parasite density/log10 μl</td><td>Hb (g/dl)</td><td>HCT (%)</td><td>MCV (fl)</td><td>MCH (pg)</td><td>MCHC (%)</td></tr><tr><td>Normal</td><td>2.97 ± 1.22</td><td>12.44 ± 2.70</td><td>37.86 ± 8.609</td><td>85.51 ± 6.68</td><td>26.87 ± 5.58</td><td>31.98 ± 2.50</td></tr><tr><td>Deficient</td><td>1.64 ± 1.55</td><td>14.15 ± 3.50</td><td>43.13 ± 10.54</td><td>85.75 ± 5.84</td><td>28.12 ± 4.92</td><td>32.43 ± 1.43</td></tr><tr><td>p-value</td><td>0.000</td><td>0.006</td><td>0.005</td><td>0.834</td><td>0.201</td><td>0.149</td></tr></table> |
58439c96c38191ba333bed0f4e7e3abd581097063d3dad8a672c07d5b5a7c087.png | simple | <table><tr><td>Variables</td><td>Adjusted odds ratio</td><td>95 % confidence interval</td><td><i>P</i></td></tr><tr><td><i>Previous-day aPTT</i><sup>a</sup></td><td></td><td></td><td></td></tr><tr><td>≥46 and ≤55 s</td><td>2.03</td><td>0.68–6.10</td><td>0.30</td></tr><tr><td>≥56 and ≤69 s</td><td>1.32</td><td>0.41–4.27</td><td>0.47</td></tr><tr><td>≥70 s</td><td>3.24</td><td>1.11–9.44</td><td>0.03</td></tr><tr><td>Previous-day anticoagulation</td><td>0.21</td><td>0.06–0.52</td><td><0.01</td></tr><tr><td>Daily lowest corporeal temperature</td><td>1.79</td><td>1.20–2.66</td><td><0.01</td></tr><tr><td>APACHE III score</td><td>1.03</td><td>1.01–1.04</td><td><0.01</td></tr></table> |
2290cea8b7ceb9b106ca950bb2d735e8905f7f014e51cdbc702d9ca4c195b243.png | simple | <table><tr><td>Protein identification</td><td>Accession number (UniProtKB/TrEMBL)</td><td>Spot</td><td>Fold</td><td>Mascot score</td><td>Sequence coverage (%)</td><td>Peptide number</td><td>Molecular mass (kDA)</td><td>pI</td></tr><tr><td>gSG6 <sup>SP</sup></td><td>Q9BIH5_ANOGA</td><td>794</td><td>1.8</td><td>14</td><td>45.22</td><td>14</td><td>13.1</td><td>5.49</td></tr><tr><td>gSG1b <sup>SP</sup></td><td>Q9BIH6_ANOGA</td><td>1197</td><td>1.6</td><td>59</td><td>46.23</td><td>59</td><td>43.6</td><td>7.58</td></tr><tr><td>Long form D7 <sup>SP</sup></td><td>Q7PJ76_ANOGA</td><td>1144</td><td>1.4</td><td>15</td><td>40.19</td><td>15</td><td>35.6</td><td>5.90</td></tr><tr><td>SG5 <sup>SP</sup></td><td>Q9BIH7_ANOGA</td><td>1228</td><td>2.0</td><td>15</td><td>29.22</td><td>15</td><td>38.2</td><td>6.47</td></tr><tr><td></td><td></td><td>1229</td><td>1.6</td><td>14</td><td>29.52</td><td>14</td><td></td><td></td></tr><tr><td>TRIO protein <sup>SP</sup></td><td>Q8WR22_ANOGA</td><td>819</td><td>1.4</td><td>12</td><td>31.46</td><td>12</td><td>43.7</td><td>6.46</td></tr><tr><td></td><td></td><td>1228</td><td>2.0</td><td>21</td><td>36.83</td><td>21</td><td></td><td></td></tr><tr><td></td><td></td><td>1229</td><td>1.6</td><td>15</td><td>29.41</td><td>15</td><td></td><td></td></tr><tr><td></td><td></td><td>1239</td><td>1.4</td><td>25</td><td>40.15</td><td>25</td><td></td><td></td></tr></table> |
0e6867868ed6fa4eca5e5a3eeb3cbdc3340d903a4f1f2cf3bf62b3f21725690a.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">Men</td><td></td><td colspan="2">Women</td><td></td></tr><tr><td>Non-NAFLD</td><td>NAFLD</td><td><i>P</i></td><td>Non-NAFLD</td><td>NFALD</td><td><i>P</i></td></tr><tr><td>N</td><td>311</td><td>214</td><td></td><td>876</td><td>610</td><td></td></tr><tr><td>Age, yr</td><td>56 (44–64)</td><td>57 (44–66)</td><td>0.723</td><td>51 (41–61)</td><td>59 (51–64)</td><td><0.001</td></tr><tr><td>Blood lead level, μg/dL</td><td>5.12 (3.30–6.90)</td><td>5.65 (4.00–7.76)</td><td>0.006</td><td>4.24 (2.80–6.24)</td><td>4.80 (3.20–6.94)</td><td><0.001</td></tr><tr><td>Blood cadmium level, μg/dL</td><td>0.15 (0.05–0.32)</td><td>0.21 (0.08–0.36)</td><td>0.017</td><td>0.14 (0.05–0.31)</td><td>0.16 (0.06–0.31)</td><td>0.295</td></tr><tr><td>ALT, U/L</td><td>19.0 (15.0–26.0)</td><td>24.0 (18.0–34.0)</td><td><0.001</td><td>15.0 (12.0–20.0)</td><td>18.0 (15.0–25.0)</td><td><0.001</td></tr><tr><td>Educational level, %</td><td></td><td></td><td>0.380</td><td></td><td></td><td>0.001</td></tr><tr><td><High School</td><td>76.0</td><td>77.9</td><td></td><td>83.9</td><td>90.5</td><td></td></tr><tr><td>High school</td><td>15.4</td><td>16.8</td><td></td><td>10.7</td><td>7.5</td><td></td></tr><tr><td>>High School</td><td>8.6</td><td>5.3</td><td></td><td>5.4</td><td>2.0</td><td></td></tr><tr><td>Waist circumference, cm</td><td>76.5 (72.0–83.0)</td><td>86.0 (82.0–92.0)</td><td><0.001</td><td>72.0 (68.0–78.0)</td><td>83.0 (77.0–89.0)</td><td><0.001</td></tr><tr><td>Body mass index, kg/m<sup>2</sup></td><td>22.5 (20.8–24.5)</td><td>26.1 (23.8–28.0)</td><td><0.001</td><td>22.4 (20.4–24.4)</td><td>26.0 (24.2–28.4)</td><td><0.001</td></tr><tr><td>LDL-cholesterol, mmol/L</td><td>2.67 (2.26–3.09)</td><td>2.92 (2.46–3.38)</td><td><0.001</td><td>2.63 (2.24–3.09)</td><td>2.97 (2.54–3.43)</td><td><0.001</td></tr><tr><td>HDL-cholesterol, mmol/L</td><td>1.39 (1.18–1.58)</td><td>1.22 (1.08–1.40)</td><td><0.001</td><td>1.51 (1.32–1.71)</td><td>1.39 (1.23–1.58)</td><td><0.001</td></tr><tr><td>Triglycerides, mmol/L</td><td>1.10 (0.86–1.49)</td><td>1.66 (1.19–2.35)</td><td><0.001</td><td>1.06 (0.81–1.46)</td><td>1.48 (1.08–2.14)</td><td><0.001</td></tr><tr><td>Total-cholesterol, mmol/L</td><td>4.84 (4.25–5.41)</td><td>5.09 (4.56–5.68)</td><td>0.001</td><td>4.87 (4.33–5.48)</td><td>5.27 (4.58–5.93)</td><td><0.001</td></tr><tr><td>Diabetes, %</td><td>9.7</td><td>15.0</td><td>0.002</td><td>5.4</td><td>19.7</td><td>0.001</td></tr><tr><td>Current smoker, %</td><td>47.1</td><td>49.0</td><td>0.681</td><td>1.8</td><td>2.3</td><td>0.524</td></tr></table> |
5b30c04bc3b604851b8564914323e59b3a721ec58bafc793f933fefd68abda63.png | complex | <table><tr><td>Study and reference</td><td colspan="2">Pack-years of smoking</td></tr><tr><td></td><td>Controls (N)</td><td>COPDs (N)</td></tr><tr><td>Bergen cohort from Pillai et al [26]</td><td>19 ± 13*(810)</td><td>32 ± 19*(823)</td></tr><tr><td>Copenhagen City Heart Study from Kaur-Knudsen et al [25]</td><td>NR</td><td>NR</td></tr><tr><td>COPDGene study from Kim et al [24]</td><td>52 ± 29*(335)</td><td>37 ± 19*(507)</td></tr><tr><td>COPACETIC cohort from Lambrechts et al [23]</td><td>38.0 (28.0-46.2) (295)</td><td>38.7 (29.7-49.5)(161)</td></tr><tr><td>LEUVEN cohort from Lambrechts et al [25]</td><td>42.3 (30.0-50.5) (184)</td><td>40.0 (30.0-57.0) (475)</td></tr><tr><td>NETT/NAS cohorts from Pillai et al [26]</td><td>40 ± 28*(472)</td><td>66 ± 30*(389)</td></tr><tr><td>New Zealand study from Young et al [27]</td><td>40 ± 19*(488)</td><td>47 ± 20*(458)</td></tr></table> |
4da201a6a1f8c062137012821983fd94faa2164279186d9862b5e11745efa9fa.png | complex | <table><tr><td>Variable category</td><td>Characteristics</td><td>n (%)</td></tr><tr><td rowspan="2">Sex</td><td>Male</td><td>90 (51.7)</td></tr><tr><td>Female</td><td>84 (48.3)</td></tr><tr><td rowspan="3">Age category</td><td>< 30</td><td>21 (12.1)</td></tr><tr><td>30–60</td><td>114 (65.5)</td></tr><tr><td>> 60</td><td>39 (22.4)</td></tr><tr><td rowspan="4">Level of educational</td><td>Illiterate</td><td>60 (34.5)</td></tr><tr><td>Primary education</td><td>74 (42.5)</td></tr><tr><td>Secondary education</td><td>35 (20.1)</td></tr><tr><td>College and above</td><td>5 (2.9)</td></tr><tr><td rowspan="3">Marital status</td><td>Single</td><td>14 (8.0)</td></tr><tr><td>Married</td><td>142 (81.6)</td></tr><tr><td>Divorced/separated</td><td>18 (10.3)</td></tr><tr><td rowspan="2">Regular follow up</td><td>No</td><td>74 (42.5)</td></tr><tr><td>Yes</td><td>100 (57.5)</td></tr><tr><td rowspan="2">Family support</td><td>Yes</td><td>63 (36.2)</td></tr><tr><td>No</td><td>111 (63.8)</td></tr><tr><td rowspan="3">Duration of diabetes treatment (years)</td><td>< 5</td><td>53 (30.5)</td></tr><tr><td>5–10</td><td>35 (20.1)</td></tr><tr><td>> 10</td><td>86 (49.4)</td></tr><tr><td rowspan="2">Co-morbidity</td><td>Yes</td><td>90 (51.7)</td></tr><tr><td>No</td><td>84 (48.3)</td></tr><tr><td rowspan="5">Type of co-morbidity</td><td>Hypertension</td><td>71 (78.9)</td></tr><tr><td>Ischemic heart disease (IHD)</td><td>10 (11.1)</td></tr><tr><td>Hypertension + IHD</td><td>5 (5.6)</td></tr><tr><td>CKD</td><td>2 (2.2)</td></tr><tr><td>Others</td><td>2 (2.2)</td></tr><tr><td rowspan="2">Diabetic complications</td><td>Yes</td><td>71 (40.8)</td></tr><tr><td>No</td><td>103 (59.2)</td></tr><tr><td rowspan="4">Type of diabetic complication</td><td>Neuropathy</td><td>31 (43.7)</td></tr><tr><td>Retinopathy</td><td>10 (14.1)</td></tr><tr><td>Retinopathy + Neuropathy</td><td>28 (39.4)</td></tr><tr><td>Retinopthy + Neuropathy + Nephropathy</td><td>2 (2.8)</td></tr></table> |
cc36b5bb77061a123d285b5c8e5f0100bd139efd3f73199655121e3398e7b832.png | simple | <table><tr><td>Brand name</td><td>Manufacturing country</td><td>Manufacturing date</td><td>Expiring date</td></tr><tr><td>Ciprocin 500</td><td>Bangladesh</td><td>September 2015</td><td>September 2017</td></tr><tr><td>Beuflox 500</td><td>Bangladesh</td><td>June 2015</td><td>May 2017</td></tr><tr><td>Neofloxacin 500</td><td>Bangladesh</td><td>August 2015</td><td>August 2018</td></tr><tr><td>Ciprox 500</td><td>Bangladesh</td><td>August 2015</td><td>August 2018</td></tr><tr><td>Quinox 500</td><td>Bangladesh</td><td>February 2015</td><td>February 2018</td></tr><tr><td>Flontin 500</td><td>Bangladesh</td><td>September 2015</td><td>September 2018</td></tr><tr><td>Floxabid 500</td><td>Bangladesh</td><td>May 2015</td><td>May 2018</td></tr><tr><td>Cipro A 500</td><td>Bangladesh</td><td>March 2015</td><td>March 2018</td></tr><tr><td>Ciprozid DS 500</td><td>Bangladesh</td><td>June 2015</td><td>June 2018</td></tr><tr><td>Rocipro 500</td><td>Bangladesh</td><td>April 2015</td><td>April 2018</td></tr></table> |
50680eb815c177f04804e6eb3713b85968767d72c0045b33a287dd8eeb898a21.png | simple | <table><tr><td>Compounds</td><td>Street</td><td>Alley</td><td>Relative Difference <sup>a</sup> (%)</td><td>Wilcoxon <i>p</i>-Value <sup>b</sup></td><td>Correlation Coefficient <sup>c</sup></td></tr><tr><td>Σ<sub>8</sub>PAH<sub>semivolatile</sub></td><td>20.59 (24.00 ± 15.49)</td><td>17.46 (20.81 ± 14.04)</td><td>16</td><td>0.002</td><td>0.93 ***</td></tr><tr><td>Pyrene</td><td>0.89 (0.94 ± 0.34)</td><td>0.83 (0.89 ± 0.33)</td><td>7</td><td>0.198</td><td>0.90 ***</td></tr><tr><td>Phe</td><td>15.50 (18.32 ± 12.35)</td><td>12.63 (15.40 ± 10.98)</td><td>21</td><td>0.001</td><td>0.94 ***</td></tr><tr><td>1-MEPH</td><td>0.58 (0.68 ± 0.41)</td><td>0.55 (0.64 ± 0.41)</td><td>5</td><td>0.109</td><td>0.94 ***</td></tr><tr><td>2-MEPH</td><td>1.14 (1.32 ± 0.80)</td><td>1.07 (1.24 ± 0.78)</td><td>6</td><td>0.064</td><td>0.90 ***</td></tr><tr><td>3-MEPH</td><td>1.27 (1.47 ± 0.93)</td><td>1.18 (1.39 ± 0.90)</td><td>7</td><td>0.084</td><td>0.94 ***</td></tr><tr><td>9-MEPH</td><td>0.81 (0.94 ± 0.59)</td><td>0.78 (0.93 ± 0.62)</td><td>4</td><td>0.363</td><td>0.96 ***</td></tr><tr><td>1,7-DMEPH</td><td>0.10 (0.13 ± 0.09)</td><td>0.10 (0.12 ± 0.09)</td><td>0</td><td>0.975</td><td>0.81 ***</td></tr><tr><td>3,6-DMEPH</td><td>0.18 (0.21 ± 0.11)</td><td>0.18 (0.20 ± 0.11)</td><td>0</td><td>0.470</td><td>0.82 ***</td></tr><tr><td>Σ<sub>8</sub>PAH<sub>nonvolatile</sub></td><td>1.32 (1.61 ± 1.04)</td><td>1.10 (1.37 ± 0.94)</td><td>18</td><td>0.011</td><td>0.90 ***</td></tr><tr><td>BaA</td><td>0.08 (0.10 ± 0.07)</td><td>0.08 (0.10 ± 0.07)</td><td>0</td><td>0.363</td><td>0.89 ***</td></tr><tr><td>Chry</td><td>0.16 (0.19 ± 0.11)</td><td>0.15 (0.18 ± 0.11)</td><td>6</td><td>0.683</td><td>0.93 ***</td></tr><tr><td>BbFA</td><td>0.31 (0.40 ± 0.26)</td><td>0.24 (0.31 ± 0.21)</td><td>25</td><td>0.002</td><td>0.83 ***</td></tr><tr><td>BkFA</td><td>0.07 (0.10 ± 0.07)</td><td>0.06 (0.08 ± 0.05)</td><td>15</td><td>0.064</td><td>0.90 ***</td></tr><tr><td>BaP</td><td>0.07 (0.09 ± 0.08)</td><td>0.07 (0.10 ± 0.09)</td><td>0</td><td>0.470</td><td>0.93 ***</td></tr><tr><td>BghiP</td><td>0.40 (0.48 ± 0.32)</td><td>0.29 (0.37 ± 0.27)</td><td>32</td><td>0.004</td><td>0.91 ***</td></tr><tr><td>IP</td><td>0.19 (0.23 ± 0.16)</td><td>0.18 (0.22 ± 0.15)</td><td>5</td><td>0.056</td><td>0.97 ***</td></tr><tr><td>Daha</td><td>0.03 (0.03 ± 0.02)</td><td>0.02 (0.02 ± 0.01)</td><td>40</td><td>0.019</td><td>0.61 ***</td></tr></table> |
4aa3c026a8a09acb4185e7191ab99c7d80f6196599858b05215cbcf7f125f44b.png | complex | <table><tr><td></td><td colspan="2">All subjects [<i>n</i> (%)]</td><td colspan="2">Subjects assessed as unexposed or probably exposed to TCE [<i>n</i> (%)]</td></tr><tr><td>Characteristics</td><td>Controls (<i>n</i> = 982)</td><td>Cases (<i>n</i> = 1,189)</td><td>Controls (<i>n</i> = 566)</td><td>Cases (<i>n</i> = 644)</td></tr><tr><td colspan="5">Age at reference date (years)</td></tr><tr><td> < 35</td><td>53 (5.4)</td><td>68 (5.7)</td><td>44 (7.8)</td><td>56 (8.7)</td></tr><tr><td> 35–44</td><td>98 (10.0)</td><td>153 (12.9)</td><td>51 (9.0)</td><td>83 (12.9)</td></tr><tr><td> 45–54</td><td>185 (18.8)</td><td>261 (22.0)</td><td>100 (17.7)</td><td>115 (17.9)</td></tr><tr><td> 55–64</td><td>230 (23.4)</td><td>316 (26.6)</td><td>136 (24.0)</td><td>174 (27.0)</td></tr><tr><td> ≥ 65</td><td>416 (42.4)</td><td>391 (32.9)</td><td>235 (41.5)</td><td>216 (33.5)</td></tr><tr><td colspan="5">Sex</td></tr><tr><td> Female</td><td>458 (46.6)</td><td>523 (44.0)</td><td>238 (42.1)</td><td>284 (44.1)</td></tr><tr><td> Male</td><td>524 (53.4)</td><td>666 (56.0)</td><td>328 (58.0)</td><td>360 (55.9)</td></tr><tr><td colspan="5">Race</td></tr><tr><td> White</td><td>787 (80.1)</td><td>1,014 (85.3)</td><td>452 (79.9)</td><td>541 (84.0)</td></tr><tr><td> African American</td><td>132 (13.4)</td><td>91 (7.7)</td><td>75 (13.3)</td><td>56 (8.7)</td></tr><tr><td> Other</td><td>63 (6.4)</td><td>84 (7.1)</td><td>39 (6.9)</td><td>47 (7.3)</td></tr><tr><td colspan="5">Study center</td></tr><tr><td> Detroit</td><td>144 (14.7)</td><td>209 (17.6)</td><td>79 (14.0)</td><td>109 (16.9)</td></tr><tr><td> Iowa</td><td>273 (27.8)</td><td>352 (29.6)</td><td>153 (27.0)</td><td>181 (28.1)</td></tr><tr><td> Los Angeles</td><td>273 (27.8)</td><td>310 (26.1)</td><td>157 (27.7)</td><td>178 (27.6)</td></tr><tr><td> Seattle</td><td>292 (29.7)</td><td>318 (26.8)</td><td>177 (31.3)</td><td>176 (27.3)</td></tr><tr><td colspan="5">Years of education</td></tr><tr><td> < 12</td><td>97 (9.9)</td><td>118 (9.9)</td><td>46 (8.1)</td><td>63 (9.8)</td></tr><tr><td> 12–15</td><td>584 (59.5)</td><td>734 (61.7)</td><td>335 (59.2)</td><td>376 (58.4)</td></tr><tr><td> ≥ 16</td><td>301 (30.7)</td><td>336 (28.3)</td><td>185 (32.7)</td><td>204 (31.7)</td></tr><tr><td> Missing</td><td>0 (0.0)</td><td>1 (0.1)</td><td>0 (0.0)</td><td>1 (0.1)</td></tr><tr><td colspan="5">Year of first employment</td></tr><tr><td> < 1950</td><td>239 (24.3)</td><td>247 (20.8)</td><td>131 (23.1)</td><td>126 (19.6)</td></tr><tr><td> 1950–1959</td><td>274 (27.9)</td><td>290 (24.4)</td><td>153 (27.0)</td><td>161 (25.0)</td></tr><tr><td> 1960–1969</td><td>225 (22.9)</td><td>284 (23.9)</td><td>118 (20.9)</td><td>131 (20.3)</td></tr><tr><td> 1970–1979</td><td>154 (15.7)</td><td>233 (19.6)</td><td>91 (16.1)</td><td>119 (18.5)</td></tr><tr><td> ≥ 1980</td><td>90 (9.1)</td><td>135 (11.4)</td><td>73 (12.9)</td><td>107 (16.6)</td></tr><tr><td colspan="5">NHL histologic typea</td></tr><tr><td> Diffuse large B-cell</td><td></td><td>366 (30.8)</td><td></td><td>211 (32.8)</td></tr><tr><td> Follicular</td><td></td><td>293 (24.6)</td><td></td><td>146 (22.7)</td></tr><tr><td> Small lymphocytic lymphoma/chronic lymphocytic leukemia</td><td></td><td>141 (11.9)</td><td></td><td>79 (12.3)</td></tr><tr><td> Other or not otherwise specified</td><td></td><td>389 (32.7)</td><td></td><td>208 (32.4)</td></tr></table> |
8f5c0dbb9a11802364dd3ba90c1fc960f6db54765d1ecf4de1d0f5f4f484fc1e.png | simple | <table><tr><td>Information</td><td>Number of bits</td></tr><tr><td>Outgoing neighbours</td><td>4</td></tr><tr><td>Hash function number</td><td>3</td></tr><tr><td>Quotient value</td><td>33</td></tr></table> |
c555bcf0f691552b3b731951d8d5f0b31a629820edaad6ecf1df99d8a72a231c.png | complex | <table><tr><td></td><td></td><td colspan="3">(<i>α</i>/<i>β</i>)<sub><i>x</i></sub> = 2 Gy</td><td colspan="3">(<i>α</i>/<i>β</i>)<sub><i>x</i></sub> = 10 Gy</td></tr><tr><td>Patient</td><td>Model</td><td>minRBE</td><td>maxRBE</td><td>meanRBE</td><td>minRBE</td><td>maxRBE</td><td>meanRBE</td></tr><tr><td>1</td><td rowspan="2">LEM<i>D</i><sub><i>t</i></sub> = 10 Gy</td><td>1.10</td><td>1.70</td><td>1.19</td><td>1.05</td><td>1.34</td><td>1.09</td></tr><tr><td>2</td><td>1.17</td><td>1.41</td><td>1.22</td><td>1.05</td><td>1.19</td><td>1.10</td></tr><tr><td>1</td><td rowspan="2">LEM<i>D</i><sub><i>t</i></sub> = 40 Gy</td><td>1.15</td><td>1.90</td><td>1.27</td><td>1.05</td><td>1.45</td><td>1.12</td></tr><tr><td>2</td><td>1.22</td><td>1.57</td><td>1.30</td><td>1.09</td><td>1.26</td><td>1.13</td></tr><tr><td>1</td><td rowspan="2">WED</td><td>1.20</td><td>1.64</td><td>1.24</td><td>1.10</td><td>1.26</td><td>1.11</td></tr><tr><td>2</td><td>1.22</td><td>1.42</td><td>1.27</td><td>1.10</td><td>1.19</td><td>1.12</td></tr><tr><td>1</td><td rowspan="2">CAR</td><td>1.20</td><td>1.60</td><td>1.27</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td></tr><tr><td>2</td><td>1.23</td><td>1.43</td><td>1.28</td></tr></table> |
442c83d5ba99066bc77b3983c4b738b3e8b2100b3375a415d1d96e62b4d78c5f.png | simple | <table><tr><td>Inclusion</td><td>Exclusion</td></tr><tr><td>Severe illness requiring intensive care</td><td>Substituted hypothyroidism (E03.0, E03.1, E03.3 E03.9, E89.0) or substitution in case of thyroid carcinoma (C73)</td></tr><tr><td>Stay of at least 24 hours at the ICU</td><td>Hyperthyroidism treated with thyrostatic agents and exhibiting a TSH level not below the reference region (E05.0 E05.9, E06.2)</td></tr><tr><td></td><td>Manifest AIDS disease (B24)</td></tr><tr><td></td><td>Pregnancy</td></tr></table> |
4696bc73a27bb9c338f8db4ffed48e15fb8eb3debfb2bc277b04fc251ac00add.png | complex | <table><tr><td rowspan="3">Variables</td><td colspan="5">Coefficient (95 % CI)</td></tr><tr><td rowspan="2">Gamma</td><td rowspan="2">Linear</td><td colspan="3">Quantile</td></tr><tr><td>Quantile 0.25</td><td>Quantile 0.50</td><td>Quantile 0.75</td></tr><tr><td>Age</td><td>0.15 (0.14, 0.17)</td><td>0.15 (0.13, 0.17)</td><td>0.11 (0.09, 0.12)</td><td>0.14 (0.12, 0.16)</td><td>0.18 (0.16, 0.21)</td></tr><tr><td colspan="6">Marital status<sup>a</sup></td></tr><tr><td> With partner</td><td>0.59 (0.28, 0.90)</td><td>0.60 (0.26, 0.93)</td><td>0.43 (0.16, 0.79)</td><td>0.54 (0.23, 0.85)</td><td>0.76 (0.39, 1.14)</td></tr><tr><td colspan="6">Race/colour<sup>b</sup></td></tr><tr><td> Brown</td><td>−0.96 (−1.51, −0.42)</td><td>−0.97 (−1.53, −0.41)</td><td>−0.43 (−0.98, 0.12)</td><td>−0.89 (−1.65, −0.14)</td><td>−1.63 (−2.30, −0.96)</td></tr><tr><td> White</td><td>−1.19 (−1.71, −0.68)</td><td>−1.23 (−1.76, −0.70)</td><td>−0.73 (−1.21, −0.25)</td><td>−1.28 (−2.03, −0.53)</td><td>−1.86 (−2.50, −1.22)</td></tr><tr><td colspan="6">Mother’s schooling<sup>c</sup></td></tr><tr><td> 9–11 years</td><td>0.21 (−0.13, 0.56)</td><td>0.21 (−0.17, 0.58)</td><td>−0.10 (−0.40, 0.20)</td><td>0.27 (−0.09, 0.62)</td><td>0.21 (−0.19, 0.61)</td></tr><tr><td> 12 or more years</td><td>0.69 (0.26, 1.12)</td><td>0.80 (0.34, 1.26)</td><td>0.42 (0.02, 0.81)</td><td>0.34 (−0.09, 0.76)</td><td>0.78 (0.13, 1.43)</td></tr><tr><td colspan="6">Domestic overload<sup>d</sup></td></tr><tr><td> High</td><td>0.60 (0.27, 0.94)</td><td>0.63 (0.28, 0.98)</td><td>0.43 (0.11, 0.74)</td><td>0.61 (0.23, 0.99)</td><td>0.89 (0.48, 1.31)</td></tr><tr><td>Years worked at night</td><td>0.03 (0.01, 0.06)</td><td>0.03 (0.01, 0.06)</td><td>0.00 (−0.03, 0.02)</td><td>0.03 (−0.01, 0.06)</td><td>0.04 (0.01, 0.07)</td></tr><tr><td colspan="6">Self-rated health<sup>e</sup></td></tr><tr><td> Poor</td><td>1.52 (1.20, 1.85)</td><td>1.62 (1.28, 1.97)</td><td>1.12 (0.79, 1.45)</td><td>1.50 (1.12, 1.87)</td><td>1.75 (1.32, 2.19)</td></tr><tr><td colspan="6">Consumption of fried food<sup>f</sup></td></tr><tr><td> 1–3×/month</td><td>1.00 (0.41, 1.58)</td><td>1.06 (0.42, 1.71)</td><td>0.93 (0.26, 1.61)</td><td>0.90 (0.25, 1.55)</td><td>0.99 (0.02, 1.96)</td></tr><tr><td> 1–3×/week</td><td>1.22 (0.64, 1.80)</td><td>1.27 (0.62, 1.91)</td><td>0.86 (0.20, 1.52)</td><td>0.95 (0.28, 1.63)</td><td>1.24 (0.24, 2.24)</td></tr><tr><td> 4–6×/week</td><td>1.41 (0.71, 2.11)</td><td>1.61 (0.84, 2.37)</td><td>1.02 (0.30, 1.74)</td><td>1.20 (0.38, 2.02)</td><td>1.55 (0.45, 2.65)</td></tr><tr><td> Daily</td><td>1.50 (0.69, 2.32)</td><td>1.42 (0.53, 2.30)</td><td>0.82 (0.13, 1.51)</td><td>1.01 (0.17, 1.84)</td><td>2.14 (0.99, 3.29)</td></tr><tr><td colspan="6">Physical inactivity<sup>g</sup></td></tr><tr><td> Yes</td><td>0.75 (0.42, 1.80)</td><td>0.80 (0.43, 1.15)</td><td>0.45 (0.17, 0.74)</td><td>0.78 (0.46, 1.10)</td><td>0.88 (0.49, 1.27)</td></tr><tr><td>BMI at age 20 years</td><td>0.93 (0.88, 0.99)</td><td>0.90 (0.81, 0.91)</td><td>0.84 (0.78, 0.90)</td><td>0.97 (0.92, 1.03)</td><td>1.09 (1.03, 1.16)</td></tr></table> |
1be8e5cb5f43071ccf8bc8f776bc81db04313cee0ef821506670f8bb4c1eaab6.png | simple | <table><tr><td> </td><td>Group A</td><td>Group B</td></tr><tr><td><i>Symptoms score (NIH-CPSI questionnaire 0–43) (±S.D.)</i></td><td> </td><td> </td></tr><tr><td>Baseline</td><td>21.85 ± 5.23</td><td>22.56 ± 5.78</td></tr><tr><td>2 months</td><td>12.00 ± 4.34</td><td>5.23 ± 2.76</td></tr><tr><td>4 months</td><td>10.48 ± 4.14</td><td>4.11 ± 2.32</td></tr><tr><td>6 months</td><td>13.26 ± 4.88</td><td>3.67 ± 1.98</td></tr><tr><td><i>Pain score (NIH-CPSI questionnaire 0–21) (±S.D.)</i></td><td> </td><td> </td></tr><tr><td>Baseline</td><td>11.65 ± 3.23</td><td>12.00 ± 2.78</td></tr><tr><td>2 months</td><td>6.20 ± 2.35</td><td>2.13 ± 1.90</td></tr><tr><td>4 months</td><td>5.82 ± 2.10</td><td>1.65 ± 1.17</td></tr><tr><td>6 months</td><td>8.06 ± 2.81</td><td>1.25 ± 0.99</td></tr><tr><td><i>Urinary score (NIH-CPSI questionnaire 0–10) (±S.D.)</i></td><td> </td><td> </td></tr><tr><td>Baseline</td><td>4.65 ± 2.11</td><td>4.26 ± 2.28</td></tr><tr><td>2 months</td><td>2.35 ± 1.35</td><td>1.34 ± 0.89</td></tr><tr><td>4 months</td><td>2.10 ± 1.15</td><td>1.11 ± 0.89</td></tr><tr><td>6 months</td><td>2.65 ± 1.44</td><td>1.01 ± 0.76</td></tr><tr><td><i>Symptoms (%)</i></td><td> </td><td> </td></tr><tr><td>Baseline</td><td>76 (100)</td><td>77 (100)</td></tr><tr><td>2 months</td><td>15 (19.7)</td><td>7 (9)</td></tr><tr><td>4 months</td><td>18 (23.7)</td><td>7 (9)</td></tr><tr><td>6 months</td><td>20 (26.3)</td><td>5 (6.5)</td></tr><tr><td><i>QoL (NIH-CPSI questionnaire 0–12) (±S.D.)</i></td><td> </td><td> </td></tr><tr><td>Baseline</td><td>5.76 ± 2.44</td><td>5.66 ± 2.39</td></tr><tr><td>2 months</td><td>2.89 ± 1.68</td><td>1.85 ± 1.00</td></tr><tr><td>4 months</td><td>2.60 ± 1.43</td><td>1.66 ± 0.95</td></tr><tr><td>6 months</td><td>3.09 ± 1.74</td><td>1.40 ± 0.94</td></tr></table> |
6ff0245864e203ae6a4d17fe3d7da1710bf370316bdf69ba152b9fca037527f4.png | simple | <table><tr><td>Candidates</td><td>Anatomical evidence to ARC or <i>Kiss1</i> neurons</td><td>ICV or electrophysiology studies</td><td>Receptors expressed in <i>Kiss1</i> neurons</td><td>Physiological relevance</td></tr><tr><td>Agouti-related peptide/neuropeptide Y (AgRP/NPY)</td><td>AgRP neurons formed synaptic connections with <i>Kiss1<sup>ARC</sup></i> neurons (mice) (135)</td><td>Channel rhodopsin-assisted mapping indicated AgRP neurons formed inhibitory synaptic connections with <i>Kiss1<sup>ARC</sup></i> neurons (mice) (135)</td><td><i>Npy1r, Npy2r</i> and <i>Npy5r</i> (82)</td><td>Chemogenetic activation of AgRP neurons inhibited fertility <i>in vivo</i> (135)</td></tr><tr><td>Arginine vasopressin (AVP)</td><td>AVP-immunoreactive fibers in close apposition with <i>Kiss1<sup>RP3V</sup></i> neurons (hamsters) (32)</td><td>AVP-stimulated <i>Kiss1<sup>RP3V</sup></i> neurons (105)</td><td><i>Avp1r</i> in <i>Kiss1<sup>RP3V</sup></i> neurons (32, 105)</td><td>Circadian AVP signaling on <i>Kiss1<sup>RP3V</sup></i> neurons is facilitated by estrogen during LH surge (32, 105)</td></tr><tr><td>Corticotropin-releasing hormone (CRH)</td><td>Close appositions of CRH-immunoreactive fibers and <i>Kiss1</i> neurons (125)</td><td>1. Central administration of CRH suppressed LH secretion in rats (117).2. CRH stimulated LH and increased GnRH pulse amplitude in sheep (118, 119)</td><td>CRHR (125)</td><td>Possible regulator of GnRH secretion in stress-induced reproductive disorders</td></tr><tr><td>Dynorphin (DYN)</td><td>DYN-immunoreactive fibers in close apposition with <i>Kiss1<sup>ARC</sup></i> neurons (rats and sheep) (171, 172)</td><td>ICV injection of dynorphin in adult male rats suppressed LH secretion (71)</td><td><i>Oprk1</i> or KOR (39, 59, 73)</td><td>Inhibitory</td></tr><tr><td>Ghrelin</td><td></td><td>1. ICV administration inhibited LH secretion (rats and sheep) (143, 144).2. Ghrelin acts on a subset of <i>Kiss1<sup>ARC</sup></i> neurons and estradiol increases the sensitivity of these neurons to ghrelin signals (mice) (147)</td><td><i>Ghsr or</i> GHSR1A (147)</td><td>Inhibitory</td></tr><tr><td>Leptin</td><td></td><td>ICV leptin treatment to fasted adult rats increased LH pulse frequency, amplitude, and mean levels (140)</td><td><i>Lepr</i> (83, 141)</td><td><i>Kiss1</i> neurons are indirect target of leptin during puberty onset (142)</td></tr><tr><td>Neurokinin B (NKB)</td><td>NKB-immunoreactive fibers in close apposition with <i>Kiss1<sup>ARC</sup></i> neurons (rats and sheep) (65, 172)</td><td>NKB increased action potential firing of <i>Kiss1<sup>ARC</sup></i> neurons <i>via</i> activation of NK3R (57–59)</td><td>NK1 tachykinin receptor (NK1R), NK2R and NK3R (58)</td><td>Stimulatory</td></tr><tr><td>Pituitary adenylate cyclase-activating peptide (PACAP)</td><td>Channel rhodopsin-assisted mapping indicated PACAP neurons from the PMV synapses onto <i>Kiss1</i> neurons (mice) (81)</td><td>1. ICV administered PACAP depressed plasma LH amplitude and pulse frequency in gonadectomized ewes (75).2. PACAP elevated the plasma LH levels in male rats (76).3. PMV PACAP neurons formed stimulatory synapses with <i>Kiss1</i> neurons (mice) (81)</td><td><i>Adcyap1r1</i> (81, 82)</td><td>Critical for ovulatory cycling and fertility in females, acts as permissive role for leptin or nutritional regulation of reproductive function (81)</td></tr><tr><td>Proopiomelanocortin/Cocaine- and amphetamine-regulated transcript</td><td>Appositions between α-MSH fibers and <i>Kiss1<sup>ARC</sup></i> neurons (rats and sheep) (131, 134)</td><td>Central alpha-MSH can stimulate or inhibit LH secretion in rats (129, 130)</td><td>MC4R (134)</td><td><i>Kiss1<sup>ARC</sup></i> neurons relay the stimulatory effects of melanocortin signaling onto the reproductive axis during puberty (134)</td></tr><tr><td>Relaxin-3</td><td>Dense relaxin-3-immunoreactive fibers projecting to the ARC (mice) (103)</td><td>ICV administration of human relaxin-3 in adult male rats stimulated LH secretion (102)</td><td><i>Rxfp 1</i> (82)</td><td>Stimulatory</td></tr><tr><td>RFamide-related peptide-3 (RFRP-3)</td><td>RFRP-3-immunoreactive fibers contacted <i>Kiss1</i> neurons (mice and rats) (33, 90)</td><td>1. ICV RFRP-3 injection inhibits LH secretion in rats (91, 92), whereas it had no effects (97) in ewes.2. Stimulates LH secretion in male hamsters (94, 95), but inhibits LH release in females (87, 93)</td><td><i>Gpr147</i> or <i>Npffr1</i> (33, 90)</td><td>Primary central target for the inhibitory action of melatonin signal on reproductive function (98)</td></tr><tr><td>Somatostatin (SST)</td><td>Appositions between SST-immunoreactive fibers and <i>Kiss1</i> neurons (sheep) (85)</td><td>Inhibits episodic LH secretion during anestrus in sheep (84).</td><td><i>Sstr1, 2, 3</i>, and <i>5</i> (82)</td><td>Inhibitory</td></tr><tr><td>Substance P (SP)</td><td>SP-immunoreactive fibers in close apposition with <i>Kiss1<sup>ARC</sup></i> neurons (monkey) (70)</td><td>1. ICV administration of SP showed increased LH release (67).2. SP activates <i>Kiss1<sup>ARC</sup></i> neurons (58)</td><td><i>Tacr1</i> or NK1R (68)</td><td>Stimulatory; critical in sustaining reproductive capabilities in female mice (66)</td></tr></table> |
4425ea195c27762dce30d0c32d3ae068376f0ebdc40cc5bddcd78bbcdb74fa45.png | simple | <table><tr><td><i>Body Site</i></td><td><i>TPS Technique</i></td><td><i>Energy</i></td></tr><tr><td>Brain</td><td>3D</td><td>6 MV, 6 MV FFF</td></tr><tr><td>Brain</td><td>IMRT, VMAT</td><td>6 MV</td></tr><tr><td>Whole Brain</td><td>3D</td><td>6 MV</td></tr><tr><td>Head and Neck bilateral</td><td>3D, IMRT, VMAT</td><td>6 MV</td></tr><tr><td>Lung ‐ Left upper lobe</td><td>3D, IMRT</td><td>6 MV</td></tr></table> |
3dd5d951cd61d3022bdf1e3d8b5bc18552dbcea0c2a421e2002f5fe55f99e9df.png | simple | <table><tr><td>Peak <sup>a</sup></td><td>Carotenoid</td><td><i>t</i><sub>R </sub><sup>b</sup> (min)</td><td>λ<sub>max</sub><sup> c</sup> (nm)</td><td>% III/II</td><td>% A<sub>B</sub>/A<sub>II</sub></td><td>[M + H]<sup>+ </sup>(<i>m/z</i>)</td><td>MS/MS fragment ions (positive mode) (<i>m/z</i>)</td><td>[M − H]<sup>−</sup> (<i>m/z</i>)</td><td>MS/MS fragment ions (negative mode)(<i>m/z</i>)</td></tr><tr><td>26</td><td>crustaxanthin</td><td>7.9</td><td>422, 449, 476</td><td>40</td><td>0</td><td>601</td><td>583 [M + H − 18]<sup>+</sup>, 565 <sup>d</sup> [M + H − 18 − 18]<sup>+</sup>, 547 [M + H − 18-18-18]<sup>+</sup>, 509 [M + H − 92]<sup>+</sup></td><td>599</td><td>581 [M − 18]<sup>−</sup>, 563 [M − 18 − 18]<sup>−</sup>, 545 [M − 18 − 18 − 18]<sup>−</sup>, 507 [M − 92]<sup>−</sup>, 493 [M − 106]<sup>−</sup></td></tr><tr><td>27</td><td>crustaxanthin</td><td>8.5</td><td>422, 449, 476</td><td>35</td><td>0</td><td>601</td><td>583 [M + H − 18]<sup>+</sup>, 565 [M + H − 18 − 18]<sup>+</sup>, 547 <sup>d</sup> [M + H − 18 − 18 − 18]<sup>+</sup>, 509 [M + H − 92]<sup>+</sup></td><td>599</td><td>581 [M − 18]<sup>−</sup>, 563 [M − 18 − 18]<sup>−</sup>, 545 [M − 18 − 18 − 18]<sup>−</sup>, 507 [M − 92]<sup>−</sup></td></tr><tr><td>28</td><td><i>cis</i>-crustaxanthin</td><td>9.0</td><td>337, 422, 449, 476</td><td>40</td><td>6</td><td>601</td><td>583 [M + H − 18]<sup>+</sup>, 565 [M + H − 18 − 18]<sup>+</sup>, 547 [M + H − 18 − 18 − 18]<sup>+</sup>, 509 [M + H − 92]<sup>+</sup></td><td>599</td><td>581 [M − 18]<sup>−</sup>, 563 [M − 18 − 18]<sup>−</sup>, 545 [M − 18 − 18 − 18]<sup>−</sup>, 507 [M − 92]<sup>−</sup></td></tr><tr><td>29</td><td><i>cis</i>-crustaxanthin</td><td>9.3</td><td>337, 420, 444, 470</td><td>20</td><td>39</td><td>601</td><td>583 [M + H − 18]<sup>+</sup>, 565 [M + H − 18 − 18]<sup>+</sup>, 547 [M + H − 18 − 18 − 18]<sup>+</sup>, 509 [M + H − 92]<sup>+</sup></td><td>599</td><td>581 [M − 18]<sup>−</sup></td></tr></table> |
d3e8f70e60982a81ff4666d98f1f1f79025dad9bbd1ad48027947f37056a0053.png | simple | <table><tr><td>Characteristic</td><td>Variable</td><td>Case</td></tr><tr><td>Gender</td><td>Male</td><td>24165</td></tr><tr><td></td><td>Female</td><td>19825</td></tr><tr><td>Site</td><td>Colon</td><td>23563</td></tr><tr><td></td><td>Rectal</td><td>20427</td></tr><tr><td>Colon</td><td>Proximal</td><td>7588</td></tr><tr><td></td><td>Distal</td><td>7305</td></tr><tr><td></td><td>unknown</td><td>8670</td></tr><tr><td>Pathologic classification</td><td>Adenocarcinoma</td><td>30845</td></tr><tr><td></td><td>Mucinous carcinoma</td><td>1716</td></tr><tr><td></td><td>Other types</td><td>1014</td></tr><tr><td></td><td>unknown</td><td>10415</td></tr></table> |
d2e1262234bdf1328f646c381565bf9dfb5b153e8af0cf8c01430e9ac293b188.png | simple | <table><tr><td> </td><td>MetS present (n = 37)</td><td>MetS absent (n = 38)</td><td>p</td></tr><tr><td>Age (years)</td><td>47 ± 6</td><td>40 ± 8</td><td><0.001</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>30.9 (24.2-42.5)</td><td>23.4 (17.6-29.8)</td><td><0.001</td></tr><tr><td>Waist circumference (cm)</td><td>107.0 (94.0-135.0)</td><td>87.0 (71.0-93.5)</td><td><0.001</td></tr><tr><td>Height (cm)</td><td>180 ± 6</td><td>180 ± 6</td><td>0.665</td></tr><tr><td>Current smokers (N, %)</td><td>13 (35)</td><td>4 (10)</td><td>0.014</td></tr><tr><td>Systolic blood pressure (mmHg)</td><td>132 ± 14</td><td>115 ± 10</td><td><0.001</td></tr><tr><td>Diastolic blood pressure (mmHg)</td><td>88 ± 9</td><td>74 ± 6</td><td><0.001</td></tr><tr><td>Total cholesterol (mmol/L)</td><td>5.25 ± 0.74</td><td>4.38 ± 0.80</td><td><0.001</td></tr><tr><td>Low-density lipoprotein cholesterol (mmol/L)</td><td>3.25 ± 0.71</td><td>2.52 ± 0.67</td><td><0.001</td></tr><tr><td>High-density lipoprotein cholesterol (mmol/L)</td><td>1.02 ± 0.26</td><td>1.50 ± 0.40</td><td><0.001</td></tr><tr><td>Triglycerides (mmol/L)</td><td>2.20 (0.65-6.26)</td><td>0.72 (0.35-1.57)</td><td><0.001</td></tr><tr><td>fP-glucose (mmol/L)</td><td>5.8 (4.6-6.9)</td><td>5.0 (4.4-6.0)</td><td><0.001</td></tr><tr><td>fS-insulin (mU/L)</td><td>9.3 (3.3-36.9)</td><td>2.9 (0.9-7.7)</td><td><0.001</td></tr><tr><td>HOMA-IR index</td><td>2.6 (0.8-8.0)</td><td>0.6 (0.2-2.0)</td><td><0.001</td></tr><tr><td>Myocardial triglyceride content (%)</td><td>0.90 (0.31-2.33)</td><td>0.43 (0.14-1.39)</td><td><0.001</td></tr><tr><td>Epicardial fat (mm<sup>2</sup>)</td><td>838 (385-1753)</td><td>518 (251-1129)</td><td><0.001</td></tr><tr><td>Pericardial fat (mm<sup>2</sup>)</td><td>1905 (615-6131)</td><td>562 (66-1582)</td><td><0.001</td></tr></table> |
6856ec8a09bfb43ae905e3e09c908ee4bd86afb3ed4fabda6c8a70dd628e4844.png | complex | <table><tr><td>Sample</td><td>Source</td><td>UId</td><td>Sex</td><td>Age</td><td colspan="4">Mutation</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>nt change</td><td>aa change</td><td>domain affected</td><td>type of mutation</td></tr><tr><td>RTT1</td><td>HBTRC</td><td>4315</td><td>F</td><td>11</td><td>c.763C>T</td><td>R255X</td><td>TRD-NLS</td><td>Nonsense</td></tr><tr><td>RTT3</td><td>HBTRC</td><td>4422</td><td>F</td><td>12</td><td>c.808C>T</td><td>R270X</td><td>TRD-NLS</td><td>Nonsense</td></tr><tr><td>RTT4</td><td>TICHR</td><td>NB</td><td>F</td><td>18</td><td>c.473C>T</td><td>T158M</td><td>MBD</td><td>Missense</td></tr><tr><td>RTT5</td><td>TICHR</td><td>KB</td><td>F</td><td>11</td><td>c.316C>T</td><td>R106W</td><td>MBD</td><td>Missense</td></tr><tr><td>RTT6</td><td>TICHR</td><td>BC</td><td>F</td><td>21</td><td>c.808C>T</td><td>R270X</td><td>TRD-NLS</td><td>Nonsense</td></tr><tr><td>RTT9</td><td>BCM</td><td>93-244</td><td>F</td><td>4</td><td>c.750insC</td><td>P251fs</td><td>TRD</td><td>Frameshift/Truncation</td></tr><tr><td>CON4</td><td>NSWTRC</td><td>88210</td><td>F</td><td>43</td><td></td><td></td><td></td><td></td></tr><tr><td>CON5</td><td>NSWTRC</td><td>88295</td><td>F</td><td>42</td><td></td><td></td><td></td><td></td></tr><tr><td>CON6</td><td>NSWTRC</td><td>88365</td><td>F</td><td>31</td><td></td><td></td><td></td><td></td></tr><tr><td>CON7</td><td>NSWTRC</td><td>88304</td><td>F</td><td>43</td><td></td><td></td><td></td><td></td></tr><tr><td>CON8</td><td>NSWTRC</td><td>9092</td><td>F</td><td>46</td><td></td><td></td><td></td><td></td></tr><tr><td>CON10</td><td>NSWTRC</td><td>12862</td><td>F</td><td>52</td><td></td><td></td><td></td><td></td></tr></table> |
c59ff8e8f2ad04deea8fdaedfc62bcbeb824eef6e94ff5400e65d8162c81114a.png | complex | <table><tr><td rowspan="2">Question</td><td colspan="4">HCW category Total, (%)</td><td></td></tr><tr><td>MDs (<i>n</i> = 20)</td><td>Nurses (<i>n</i> = 77)</td><td>PA (<i>n</i> = 4)</td><td>Overall (<i>n</i> = 101)</td><td>χ<sup>2</sup>, <i>p</i>-value</td></tr><tr><td colspan="5">Whether facility is equipped to handle EVD cases</td><td>2.66, 0.62</td></tr><tr><td> Yes</td><td>4 (3.96)</td><td>21 (20.79)</td><td>1 (0.99)</td><td>26 (25.74)</td><td rowspan="3"></td></tr><tr><td> No</td><td>14 (13.86)</td><td>39 (38.61)</td><td>2 (1.98)</td><td>55 (54.46)</td></tr><tr><td> I don’t know</td><td>2 (1.98)</td><td>17 (16.83)</td><td>1 (0.99)</td><td>10 (19.80)</td></tr><tr><td colspan="5">Whether health staff agrees to be isolated or not</td><td>4.69, 0.321</td></tr><tr><td> Yes</td><td>19 (18.81)</td><td>75 (74.26)</td><td>4 (3.96)</td><td>98 (97.03)</td><td rowspan="3"></td></tr><tr><td> No</td><td>0 (0)</td><td>2 (1.98)</td><td>0 (0)</td><td>2 (1.98)</td></tr><tr><td> Maybe</td><td>1 (0.99)</td><td>0 (0)</td><td>0 (0)</td><td>1 (0.99)</td></tr><tr><td colspan="5">Willingness to attend to an EVD patient</td><td>8.03, 0.09</td></tr><tr><td> Yes</td><td>9 (8.91)</td><td>36 (35.64)</td><td>0 (0)</td><td>45 (44.55)</td><td rowspan="3"></td></tr><tr><td> No</td><td>6 (5.94)</td><td>25 (24.75)</td><td>4 (3.96)</td><td>35 (34.65)</td></tr><tr><td> Maybe</td><td>5 (4.95)</td><td>16 (15.84)</td><td>0 (0)</td><td>21 (20.79)</td></tr><tr><td colspan="5">Whether health staff is adequately trained or not</td><td>0.98, 0.614</td></tr><tr><td> Yes</td><td>1 (0.99)</td><td>8 (7.92)</td><td>0 (0)</td><td>9 (8.91)</td><td rowspan="2"></td></tr><tr><td> No</td><td>19 (18.81)</td><td>69 (68.32)</td><td>4 (3.96)</td><td>92 (91.09)</td></tr><tr><td colspan="5">Confidence level in handling an EVD suspected patient</td><td>13.09, 0.11</td></tr><tr><td> No confidence</td><td>3 (2.97)</td><td>15 (14.85)</td><td>1 (0.99)</td><td>19 (18.81)</td><td rowspan="5"></td></tr><tr><td> Little confidence</td><td>10 (9.90)</td><td>13 (12.87)</td><td>1 (0.99)</td><td>24 (23.76)</td></tr><tr><td> Confident</td><td>3 (2.97)</td><td>29 (28.71)</td><td>1 (0.99)</td><td>33 (32.67)</td></tr><tr><td> Very confident</td><td>3 (2.97)</td><td>15 (14.85)</td><td>0 (0.99)</td><td>18 (17.82)</td></tr><tr><td> Extremely confident</td><td>1 (0.99)</td><td>5 (4.95)</td><td>1 (0.99)</td><td>7 (6.93)</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.